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ABSTRACT OF THE DISSERTATION 
Elucidating the Effect of Myopathy-Causing Mutations and Second-Site Suppressors  
on Client Processing by J-Domain Proteins 
by 
Melanie Yainés Pullen-Colón 
Doctor of Philosophy in Biology and Biomedical Sciences 
Developmental, Regenerative, and Stem Cell Biology 
Washington University in St Louis, 2020 
Professor Heather True, Chair 
Professor James Skeath, Co-Chair 
Defects in protein quality control may lead to protein misfolding and aggregation often 
associated with protein conformational disorders such as Alzheimer’s Disease and Limb Girdle 
Muscular Dystrophy, among others. Molecular chaperones protect against protein misfolding and 
aggregation. A chaperone of interest is the ubiquitously expressed type II Hsp40 co-chaperone 
DNAJB6, which assists in protein folding and disaggregation. Mutations within the DNAJB6 
G/F domain have been associated with the dominantly inherited disease Limb-Girdle Muscular 
Dystrophy type 1D (LGMD1D), now referred to as LGMDD1. Our collaborators recently 
discovered novel LGMDD1-associated mutations in the J-domain of DNAJB6. In the enclosed 
body of work, we used yeast as a model to perform phenotypic, biochemical and functional 
assays to elucidate the effect of the J-domain mutations on canonical chaperone function with the 
xiv 
 
goal of beginning to understand how mutations in this domain may affect LGMDD1 
pathogenesis. Moreover, we have identified second-site suppressors that rescue a viability defect 
in yeast that is associated with a myopathy-causing mutation. With this work we have begun to 
assess the ways in which second-site suppressors may be therapeutic for inherited myopathies 
such as LGMDD1. 
The heat shock response is a highly conserved program from yeast to mammals, thus, we 
have used a yeast model system to study disease-causing mutations. The yeast type II Hsp40 co-
chaperone, Sis1, is homologous to DNAJB6 and has an important role in yeast for the 
propagation of two yeast prions, [RNQ+] and [PSI+]. The True lab has previously published 
work showing that when LGMDD1-associated mutations in the G/F domain are present in Sis1, 
its client processing function is altered. Since novel J-domain mutations have yet to be 
characterized, we assessed the effect of these mutations using our yeast model. Here, we provide 
evidence that novel variants in the Hsp40 J-domain lead to aberrant chaperone function and 
altered protein homeostasis in a client and conformer specific manner. Moreover, we identified a 
novel client-dependent viability defect when one of the J-domain mutants is expressed. This is 
the first time, to our knowledge, that steady-state levels of a mutated chaperone have been shown 
to be dependent on stabilization by a client. Lastly, we have identified and began to characterize 
second-site suppressors which may lead future studies into using second-site suppressors for 
therapeutic purposes. 
This body of work enables direct comparisons between disease-associated mutants in 
different domains so that we may begin to not only understand how LGMDD1 mutants could 
impact disease severity and pathogenesis, but also whether similar therapeutic avenues could be 
explored to treat patients with different mutations in the future. 
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Chapter 1: Background and Significance 
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1.1 Overview 
Molecular chaperones are involved in maintaining protein homeostasis. Protein misfolding is 
an event that occurs naturally within the cell and when such an event happens, proteins are likely 
to form aggregates which are deleterious to cell function. It is the role of molecular chaperones 
to help resolubilize aggregates and successfully refold these polypeptides into their properly 
folded protein structure. If canonical chaperone function is altered this may result in protein 
aggregates associated with disease. One such example is the autosomal dominant, Limb girdle 
muscle dystrophy type 1D (LGMDD1). LGMDD1 is associated with mutations in the Hsp40 
chaperone DNAJB6. This disease can be modeled using mice, cell and tissue cultures, as well as 
the yeast prion system. Prions in yeast are naturally occurring, non-cytotoxic and, most 
importantly, include known clients of Hsp40 chaperones, [PSI+] and [RNQ+]. Since molecular 
chaperones are required for prion propagation, adequate propagation of such amyloids serves as 
a readout for chaperone function. Thereby, homologous mutations in yeast Hsp40 chaperones 
can be assessed for defects in client processing within this system. Studying aberrant molecular 
chaperone function with regard to disease-associated mutations will allow us to identify the 
cause of disease pathogenesis and improve our understanding of the disease and potential 
therapeutic approaches.  
1.2 Protein Misfolding and Protein Conformational 
Disorders 
1.2.1 Protein misfolding 
Proteins are necessary for, and involved in, every biological process. The ability to properly 
synthesize and fold proteins is essential for their function and, ultimately, for the survival and 
well-being of organisms (1). Unsurprisingly, inadequate protein folding has negative 
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consequences leading to cellular malfunction and disease. As such, many diseases are thought to 
arise from protein misfolding and subsequent aggregation (2, 3). Many of these diseases have 
genetic origins; mutations in the polypeptide sequence likely alter the stability or protein 
kinetics, in turn, disrupting the correct function of the protein or their quality control systems.  
Overall, protein misfolding is a common cellular event occurring throughout the lifetime of 
a cell, which is why mechanisms have evolved to cope with misfolded proteins. Furthermore, the 
in vivo folding, transport, and degradation of proteins often involves a variety of conformational 
transitions. For example, during protein synthesis, a polypeptide chain will emerge from the 
ribosome and can either be: folded into its native state spontaneously or with the help of 
molecular chaperones, degraded by either the ubiquitin-proteasome or autophagy-lysosome 
pathways, or, alternatively, form highly insoluble fibrils which may aggregate and accumulate in 
tissue (4, 5). 
Protein quality control (PQC) systems are crucial for protein homeostasis and require 
molecular chaperones and co-chaperones to efficiently process misfolded proteins (6). There are 
multiple systems by which PQC can mediate protein turnover. One such system is the highly-
specific ubiquitin-proteasome system (UPS) (7). The UPS is the principal system targeting 
soluble proteins. Herein proteins are tagged with polyubiquitin chains, which are highly 
conserved in eukaryotes and necessary for recognition by the proteasome. Once the proteasome 
recognizes these ubiquitin-marked proteins, they are degraded (8, 9). Alternatively, the less 
specific autophagy-lysosome system can degrade soluble proteins and larger, more complex 
structures such as protein aggregates, macromolecules or organelles (10, 11). In this system, such 
structures are delivered to lysosomes or endosomes for degradation. Understandably so, defects 
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in one or many of these steps will lead to aberrant quality control systems and as such could lead 
to pathogenesis (12). With regard to the main topic of this dissertation, we will now focus our 
discussion on protein conformational disorders, such as chaperonopathies, that occur based on 
improper protein folding due, in part, to improper chaperone function.  
1.2.2  Protein conformational disorders 
Protein conformational disorders are defined by an inability to properly synthesize, fold and 
maintain the proteome. These disorders are wide-ranging and can be subdivided into three 
general categories: neurodegenerative diseases, non-neuropathic diseases and systemic disorders 
(13, 14). Examples of such protein conformational disorders resulting from defects in protein 
quality control include Alzheimer’s, Huntington’s, Parkinson’s, Creutzfeldt-Jakob disease and 
Limb Girdle Muscular Dystrophy, among others (15). Some of these diseases occur as familial 
cases, while others occur sporadically. Interestingly, a subset of neurodegenerative diseases 
occur through infection, such as prion diseases, or transmissible spongiform encephalopathies 
(16).  
Many of the bodily systems affected by these diseases, such as the neuromuscular system, 
are mostly comprised of post-mitotic, terminally differentiated cells. Understandably, because 
these cells are needed for adequate physiological function throughout life, they rely heavily on 
PQC systems for adequate protein turnover and efficient cell function. Therefore, proteostasis 
requires adequate protein synthesis and folding, post-translational modifications, and clearance. 
Any aberrant PQC pathway could disrupt proteostasis, causing devastating effects to this system 
and potentially leading to disease (12). Thankfully, the PQC system has evolved to have a wide-
array of readily available chaperones and co-chaperones with crucial roles.  
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An increasing number of mutations in chaperones have been linked to a variety of disorders 
with, for example, many neuromuscular disorders arising from or involving aberrant chaperone 
and/or co-chaperone gene function and expression (17). Disorders caused by mutations in 
chaperones are referred to as chaperonopathies (18). Without adequate chaperone or co-
chaperone function, essential, improperly folded proteins may become non-functional and thus 
may affect cellular viability. Indeed, over 50% of all known chaperonopathies are due to 
mutations in  chaperones of the J-domain protein (JDP) family (Figure 1.1) (19). 
One such example of chaperonopathies is the autosomal dominant disease Limb Girdle 
Muscular Dystrophy Type 1D (LGMDD1). LGMDD1 is associated with various mutations 
identified in the type II Hsp40, DNAJB6 (20–23). It has been reported that mutations in a variety 
of chaperones cause other types of dominantly inherited chaperonopathies (24–27). Overall, it 
seems that aberrant chaperone function, particularly in tissues such as skeletal muscle contributes 
to pathogenesis in a wide range of myopathies (28). Myopathies will be further discussed in 
section 1.5. 
1.3  Molecular Chaperones 
A complex and highly-conserved network of molecular chaperones has evolved to help 
maintain protein homeostasis by impeding protein misfolding and protein aggregations that often 
lead to disease (29). Heat shock proteins are ubiquitous across all domains of life, classified by 
families and named by their molecular weight as small HSPs (sHSP), HSP40, HSP70, and 
HSP100s (30). Originally identified due to heat shock stress response, molecular chaperones 
maintain protein homeostasis by aiding protein folding during translation and by assisting 
misfolded proteins in recovering their correct conformation (31, 32). In addition, molecular 
chaperones also play an important role in the propagation of all yeast prions (32–34). 
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The heat shock response is highly conserved (30). HSPs are constitutively expressed and 
increase in expression to assist in protein refolding as a response to an increase in the amount of 
misfolded proteins due to stressors. In a deficient chaperone network, proteins that misfold may 
aggregate and lead to toxicity. Unsurprisingly, any deficiencies in these systems can lead to 
disease. When amyloidogenic proteins misfold, this can result in formation of a self-
perpetuating, toxic prion conformation that enhances aggregation of other monomeric proteins 
(35). The following section will focus on three major types of molecular chaperones, namely, 
Hsp104, Hsp70 and J-domain proteins. Furthermore, in this section, I will focus on two specific 
members of the J-domain protein family, the mammalian protein DNAJB6 and the yeast protein 
Sis1. 
1.3.1 Hsp104 
The molecular chaperone Hsp104 is a complex ATPase of the yeast AAA+ superfamily. 
This molecular chaperone is involved in protein disaggregation and is required for propagation 
of all known cytoplasmic yeast prions (36–40). Hsp104 is composed of six subunits forming a 
hexametric central pore which allows threading of substrates through the refolding channel (41–
43). Hsp104 has five domains: an N-terminal domain followed by two nucleotide-binding AAA+ 
domains, a coiled-coil MD and a C-terminal extension (44, 45). Of note, extensive work from the 
Lindquist lab has characterized Hsp104 and identified that it is only functional in its hexametric 
conformation (46–48). 
Hsp104 can disaggregate disordered aggregates in addition to stable amyloids, although 
the mechanism is different for each type. In order to disaggregate disordered aggregates, the 
Hsp104 subunits within the hexamer will collaborate noncooperatively. Resolving ordered 
aggregates, in contrast, requires Hsp104 subunits to cooperatively engage the substrate and ATP 
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hydrolysis (49). This plasticity allows Hsp104 to interact with different types of substrates (50). 
The activity of Hsp104 is optimized in the presence of the yeast Hsp70 co-chaperone system (37, 
51, 52). 
Hsp104 disaggregation activity is essential for the propagation of yeast prions (45, 53). 
For example, we will discuss the mechanism by which Hsp104 fragments Sup35 prions. Sup35 is 
a translation termination factor that aggregates to form the prion [PSI+]. Generally, Hsp104 
binds to a specific region of the Sup35 prion N and M domains but does not unfold regions C-
terminal of these (50). Interestingly, in vivo studies have shown that Hsp104 overexpression 
cures yeast of some prions, including [PSI+] (54).  Moreover, inhibition of Hsp104 activity 
through addition of guanidine hydrochloride (GdnHCl) leads to loss of prion propagation 
(curing) (55). Of note, deletion of Hsp104 is not lethal under normal conditions but there are 
growth defects that occur when deleted under stress conditions, highlighting the importance of 
Hsp104 for homeostasis (56). The human complex composed of Hsp110/Hsp70/J-domain 
protein has been able to promote alpha-synuclein depolymerization in vitro (57). Remarkably, 
the yeast Hsp104 has no obvious ortholog in multicellular organisms (58). The importance of 
Hsp104 for prion propagation will be further discussed in section 1.4. 
1.3.2 Hsp70s & NEFs 
The ubiquitously expressed 70kD heat shock proteins (Hsp70s) are conserved from 
bacteria to humans where multiple Hsp70s are expressed (59). For example, in humans there are 
13 Hsp70 homologs with isoforms regulated and expressed at different levels depending on 
cellular needs (60). Hsp70 chaperones have a wide range of functions including folding newly-
synthesized proteins, translocation of polypeptides, disassembly of complexes, and regulation of 
protein activity. Importantly, Hsp70 participates in properly refolding and preventing 
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aggregation of misfolded proteins. An Hsp70s functional diversity is further increased by 
cooperation with other co-chaperones. Molecular Hsp70s have many essential functions and are 
often associated with disease (61). 
The structure of Hsp70 chaperone family members consists of an N-terminal nucleotide 
binding domain (NBD), a substrate binding domain (SBD), and a disordered C-terminal variable 
domain (VD) which, in eukaryotes, often ends with a conserved Glu-Glu-Val-Asp (EEVD) motif 
(62, 63). Given the role of Hsp70 in promoting the adequate refolding of misfolded proteins, its 
activity requires adequate association and subsequent release of these polypeptides. In order to 
do so, Hsp70s undergo a mechanism or cycle by which they interact with substrates (Figure 1.2) 
(61). Specifically, the Hsp70 cycle consists of an allosteric system through which ATP 
hydrolysis in the NBD is coupled to substrate binding in the SBD. In an ADP-bound state the 
SBD is bound to a peptide, which is in turn now protected from cytoplasmic interaction (64, 65). 
ATP binding to the NBD leads to opening of the SBD and an increase in disassociation rate, 
which leads to release of the substrate (66). Hsp70s have been shown to have innate ATPase 
activity although it is low and often necessitates assistance of other chaperones, such as J-domain 
protein co-chaperones, for adequate substrate interaction. J-domain protein co-chaperones will be 
further discussed in section 1.3. 
In addition to J-domain protein co-chaperones, the activity of Hsp70s is also regulated by 
nucleotide exchange factors (NEFs) (66). In the Hsp70 cycle, NEFs mediate the opening of 
HSP70’s nucleotide binding cleft by facilitating the release of ADP; this, in turn, promotes the 
release of the substrate. In the cytosol of eukaryotes, NEFs belong to three protein families 
(Hsp110/Grp170, HspBP1/Sil1, and BAG protein families) and are responsible for nucleotide 
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exchange by stabilizing the open conformation of the NBD (66). Interestingly, some NEFs, such 
as Fes1, have also been shown to prevent the unproductive rebinding of the released substrate to 
Hsp70 by blocking the SBD (67). 
Hsp70s have many functions, one of which is assisting in de novo protein folding by 
delaying the folding of polypeptides emerging from the ribosome until the emerging domain can 
be adequately folded, thus preventing nascent chain aggregation (68). Other important roles for 
Hsp70s include substrate handover to other PQC machinery, protein translocation and assembly 
and disassembly of protein complexes. Of relevance to this work, Hsp70s play an important role 
in protein disaggregation (69). For example, Hsp70 has been shown to recruit Hsp100-type 
disaggregases to the surface of protein aggregates allowing for activation of an ATP-hydrolysis 
driven mechanism in Hsp100 (70). This mechanism allows the Hsp100 to thread trapped 
polypeptides through its central pore thereby resolving aggregated proteins. Of note, a major 
subfamily of Hsp70 in yeast propagation is Ssa. This chaperone subfamily consists of four 
chaperones. Namely, Ssa1 is expressed during vegetative growth and is stress-induced, Ssa2 is 
constitutively expressed, the other two members, Ssa3 and Ssa4, are stress-inducible only (71). 
All Ssa subfamily members can help propagate the Sup35 prion, [PSI+], in yeast (72). 
1.3.3 J-Domain Proteins (JDPs) 
J-domain proteins (JDPs), also known as Hsp40s, are modular multidomain proteins 
characterized by their highly conserved J domain. Mainly, J-domain proteins act as catalysts of 
Hsp70s and are responsible for substrate identification and delivery. Studies have linked J-
domain proteins to pathological conditions including cancer, neurodegenerative diseases, 
muscular dystrophy and viral infection (73–76). The human genome encodes more than 40 J 
domain proteins (77). For comparison, there are 22 J-domain proteins in yeast (78) 13 of which 
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are cytoplasmic (79, 80). Interestingly, some J-domain protein chaperones are required for 
viability in yeast, such as Sis1, Jjj1 and Cwc23, while others are not (80). It is believed for all 
systems that the diversity of J-domain protein chaperones allows for specificity and gives 
Hsp70s access to a multitude of substrates. 
J-domain proteins have been historically divided into three classes (A, B, and C), based 
on their similarity to the bacterial (E. coli) protein DnaJ (Figure 1.3) (60). Class A J-domain 
proteins contain an N-terminal J-domain followed by a ~30 residue glycine/phenylalanine (G/F)-
rich region, two beta-barrel domains including a zinc finger-like region (ZFLR) and a conserved 
C-terminal dimerization domain (CTD) (19). Class B J-domain proteins are similar to the 
previously described Class A J-domain proteins but, instead of the ZFLR, there is a 
glycine/methionine region. Additionally, some proteins in Class B have a serine/threonine (S/T) 
rich domain between the G/F-rich region and the CTD (81). Class C J-domain proteins only 
share the J-domain region with DnaJ and encompass all J-domain proteins that do not belong to 
class A or B (82). Some J-domain proteins are able to form hetero-dimers, while others, such as 
Sis1, form homo-dimers (83). 
An important role for J-domain proteins is interacting with Hsp70s and subsequently 
stimulating ATP hydrolysis (77, 79, 84). This interaction between J-domain proteins and Hsp70 
occurs through the helices I and II of the J-domain protein’s J-domain; there, a loop contains the 
conserved histidine-proline-aspartate (HPD) motif that is essential for stimulation of Hsp70 
ATPase activity (85). The J-domain binds to the Hsp70 at NBD-SBD interface. This allows the 
HPD motif to interact with key HSP70 residues, promoting ATP hydrolysis and conversion to a 
conformation with high affinity for substrates (84, 86) (Figure 1.2). In addition, the J-domain 
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protein interacts with the Hsp70 EEVD motif, which seems to be a crucial interaction for the J-
domain protein/70 cycle to occur (86).  In addition to stimulating ATP hydrolysis, J-domain 
proteins bind directly to substrates in order to present them to Hsp70 (77). Interestingly, binding 
of a substrate to a J-domain protein increases the number of available Hsp70 binding sites for 
that substrate (87, 88). 
There are still many gaps in knowledge pertaining to the structural requirements involved 
in the functional interaction between J-domain proteins and Hsp70s. For one, we know that the J-
domain of J-domain proteins is a defining feature for these co-chaperones and that all J-domain 
proteins have the conserved HPD motif necessary for interaction with Hsp70. Nonetheless, how 
a specific J-domain protein interacts with its particular Hsp70 partner is still unknown.  
Another defining region for class A and B J-domain proteins is the flexible 
glycine/phenylalanine (G/F)-rich region. The G/F-rich region is yet another incompletely 
understood region of these proteins. Work done to elucidate the function of this region hints that 
it could be involved in modulating the substrate binding activity of Hsp70 (89). Others have 
shown that the G/F-rich region may even be involved in substrate binding (90). It is clear that 
this region offers some essential purpose required for the adequate function of these proteins, 
given the fact that mutations within the G/F-rich domain have been associated with heritable 
myopathy (75). J-domain proteins are incredibly diverse beyond the J-domain and the G/F-rich 
domain. It is believed that other domains impart essential roles such as intracellular localization, 
membrane association and substrate binding (91). 
Furthermore, in the context of this dissertation, it is important to further understand two 
Class B J-domain proteins, namely, the mammalian DnaJB6 protein and the yeast Sis1 protein. 
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These proteins, and their importance with regard to this dissertation, will be further addressed in 
the two following subsections: 1.3.4 and 1.3.5. 
1.3.4 DNAJB6 
A molecular chaperone of particular interest to us is the ubiquitously expressed Class B J-
domain protein co-chaperone, DNAJB6, which assists in protein folding and disaggregation (90). 
In humans, this protein exists as two alternatively spliced isoforms, namely, DNAJB6a (36kDa) 
and DNAJB6b (27kDa), the main difference being in the length of their CTD (Figure 1.4). The 
longer DNAJB6a isoform contains a nuclear localization signal in the CTD (92). In contrast, the 
DNAJB6b isoform is shorter and exhibits both cytosolic and nuclear localization (93). 
Particularly, for DNAJB6b, nuclear accumulation has been shown after heat shock (94). 
DNAJB6 is widely expressed throughout human tissue and, surprisingly, although DNAJB6 has 
been implicated in myopathy, there appears to be low overall expression in skeletal muscle (93).  
DNAJB6 has been implicated in many cellular functions, particularly as a cochaperone, 
but most interestingly, as having an important role for anti-aggregation. Remarkably, DNAJB6 
has been recognized for its efficient suppression of amyloidogenic protein aggregates (95, 96). 
Work from the Kampinga lab has identified the ability of DNAJB6 to inhibit polyQ aggregation, 
as well as nucleation and formation of amyloid fibrils, due to its hydroxyl groups in the S/T 
motif (97). 
Mutations in J-domain proteins, including DNAJB6, are associated with inherited 
neuropathies (28, 98, 99). Indeed, mutations within a 12 amino acid region of the DNAJB6 G/F 
domain increase the protein’s half-life and reduce its anti-aggregation effects (20–22). These 
mutations are associated with limb-girdle muscular dystrophy type 1D (LGMDD1), a dominantly 
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inherited degenerative muscle disease distinguished by protein aggregate accumulations in 
muscle (20–23). The role of mutations in DNAJB6 on LGMDD1 will be discussed in greater 
detail in section 1.5. 
1.3.5 Sis1 
Sis1 is an essential, yeast Class B J-domain protein, homologous to DNAJB6. Sis1 is one 
of two major cytosolic J-domain proteins with an important role in the propagation of prions 
[RNQ+], [PSI+] and [URE3] (85, 86, 100–103) (85, 86, 100–102). Structurally, Sis1 appears to 
form a homodimer through a short stretch of the C-terminal domain (104). Because Sis1 is a J-
domain protein, it is an obligatory co-chaperone of Hsp70 by stimulating ATP hydrolysis and 
stabilizing its interaction with substrate. In yeast, the major partner of Sis1 is the Hsp70 
chaperone Ssa.  
Studies by the Craig lab have shown that Sis1 cooperation with Hsp70 requires binding 
of the Sis1 J-domain to the Hsp70 EEVD motif for in vitro protein refolding (86). Moreover, 
they also found that the interaction of two residues, E50 and R73, located in the J-domain and in 
the G/F-rich domain, respectively, is crucial for adequate protein function. These findings 
highlight the importance of the intramolecular interactions between the J- and G/F-domains of 
Sis1 (86). Although Sis1 is essential, studies have shown that Sis1 expression may be reduced 
while maintaining viability (100). Nonetheless, it appears that prion propagation is much more 
sensitive to a reduction of Sis1 levels; Sis1 repression allows for growth, though [RNQ+] prions 
are cured after ~20 generations and [PSI+] prions require more than 50 generations for curing 
(100). Because Sis1 is required for adequate prion propagation, additional studies have focused 
more specifically on which protein domains of Sis1 are required for prion propagation. As such, 
studies have shown that deletion of the G/F-rich region abolished [RNQ+] propagation, as does 
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the C-terminal domain region in the 74d-694 strain background, but not the W303 strain 
background (102). 
Due to the homology between Sis1 and DNAJB6, and the opportunities that the yeast 
prion system offers, we have studied the effects of disease-associated mutations through this 
approach. Prions in yeast are epigenetic elements that form when the prion proteins form 
amyloid aggregates. These prion aggregates are propagated by fragmentation into propagons, 
which are then passed on to progeny during mitosis (37). Somewhat counterintuitively, 
chaperones, such as Sis1, not only promote prion propagation in yeast, but are essential for it (37, 
105–108). At the heart of this chaperone-mediated process is Sis1, as the interaction between J-
domain proteins and Hsp70 chaperones is required for prion propagation in yeast (33, 34, 106, 
109–112). When chaperone function is defective, prion propagation is impaired (100, 113–116). 
Thus, the loss of prion propagation provides a read-out for chaperone dysfunction in yeast. 
In using the yeast prion system to study the effect of disease-associated mutations in the 
homologous Sis1 protein, previous work from the True lab has modeled DNAJB6 G/F domain 
mutants in yeast, using an SDSS chimera (117). This chimera consists of the J-domain, G/M 
domain and C-terminal domain of Sis1 and the G/F domain of DNAJB6. With the use of WT 
SDSS, yeast growth is supported in the absence of Sis1, and SDSS can support [RNQ+] 
propagation. This confirms that the G/F domain of DNAJB6 can functionally replace that of 
Sis1. Furthermore, work by the True lab generated LGMDD1 mutants in SDSS and replaced 
wild-type (WT) Sis1 in these cells, demonstrating that LGMDD1 mutants in SDSS only 
propagated certain prion strains (117). Studies such as these have allowed us to better understand 
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the function of J-domain proteins, while also elucidating the effect of disease-associated 
mutations on canonical chaperone function.  
1.4 Prions and Prion Propagation 
1.4.1 Prions in yeast:  S. Cerevisiae as a Model System 
 There are several proteins in yeast that form non-toxic prions comprised of characteristic 
amyloid structures present in human diseases. These proteins have regions rich in glutamine and 
asparagine (Q/N) and prion-forming domains (PFD) necessary for prion maintenance (35, 37). 
Overall, yeast prions serve as a simple, non-toxic model system to study mechanisms of amyloid 
formation and propagation applicable to human diseases. There are determined characteristics 
that define whether a phenotype is a bona-fide prion. These requirements include that the 
phenotype is: 1) dependent on production of the determinant protein, 2) caused by an alteration 
of the protein’s canonical function, 3) infectious through cytoductions, dominant in crosses and 
does not follow the classic mendelian rules of inheritance, and  4) reversibly curable. 
Remarkably, the propagation of yeast prions is maintained by the same J-domain 
protein/Hsp70/Hsp104 chaperone machinery that is involved in protein quality control 
mechanisms. Given that yeast prions manifest as protein-based heritable elements, one of the 
advantages of the yeast system lies within the ability to perform genetic screens that provide 
valuable information on viable alternatives to reverse the effects of deleterious mutations of 
molecular chaperones (37). The three most studied prions in S. cerevisiae are [PSI+], [RNQ+] 
and [URE3]. Herein, we will describe in more detail the yeast prions [PSI+] and [RNQ+] in 
section 1.4.2 and 1.4.3, respectively.  
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The yeast prion model offers a unique opportunity to evaluate DNAJB6 mutant 
dysfunction on protein aggregate phenotypes in a tractable system. As explored in this 
dissertation, by studying intragenic changes that may rescue the harmful effect of LGMDD1 
mutations we can identify therapeutic strategies to treat disease. Historically, the S. cerevisiae 
model system has allow for identification on disease mechanisms and potential therapeutic 
targets for neurodegenerative diseases, among others (118–122). With the insights gained from 
yeast genetics and biochemistry we can immediately translate these findings to cell culture, 
animal models and ultimately, patient care.  
With regard to yeast and how molecular chaperones in this system can be used as a model 
for understanding human disease, it begs the question: how similar are these chaperone networks 
in these two different species? Molecular chaperones that belong to the J-domain protein and 
Hsp70 families in yeast have been found to be conserved from yeast to humans (30). An example 
is the constitutive human Hsc70 chaperone, which is analogous to the yeast Hsp70 and has been 
found to support yeast viability and [PSI+] propagation (in the absence of Ssa) (123). 
Furthermore, mutations in the human J-domain protein DNAJB6 are associated with myopathy 
and previous work from our lab has shown homologous mutations in the yeast system affect 
[PSI+] and [RNQ+] propagation in yeast (117). Similarly, J-domain proteins have also been 
shown to modulate aggregation of neurodegenerative disease-associated proteins such as 
polyglutamine and TDP-43 (28, 117, 124–129). Because of the homology and the ability to 
support their functions in either organism, it is believed that these molecular chaperones play 
similar roles in yeast and in humans with regard to modulation of amyloid-like aggregation. 
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1.4.2 The yeast prion [PSI+] 
 Yeast prions are amyloid aggregates of misfolded proteins. For example, Sup35p, a 
translation termination factor in Saccharomyces cerevisiae, can “misfold” to form a self-
propagating aggregate: the [PSI+] prion, formed from the soluble protein Sup35p (130). The 
prion form is specified by uppercase denotation within brackets ([PSI+]), the non-prion state is 
denoted as lowercase within the brackets ([psi-]). When Sup35p is sequestered into aggregates it 
cannot bind to its cofactor, Sup45p, causing read-through of stop codons (nonsense suppression). 
Interestingly, the de novo conversion of Sup35p to form [PSI+] is regulated in vivo by another 
yeast prion termed [RNQ+] (also known as [PIN+]), formed by the Rnq1 protein, which 
currently has no known function (131, 132). This is suggested to occur through cross-seeding, in 
which the [RNQ+] prion serves as a template that associates with Sup35p to seed the induction of 
[PSI+] although, once the [PSI+] prion forms, [PSI+] and [RNQ+] propagate independently 
(132).  
Prions can have multiple conformations, also known as prion variants or strains, each 
with different heritable traits. For example, [PSI+] prions have multiple variants of prion 
conformation such as: “weak [PSI+]” and “strong [PSI+]”, distinguished by the efficiency of 
nonsense suppression (133). It has been shown that the Sup35 N-domain affects the phenotype 
(variants) and formation of [PSI+]. In addition, the presence of [RNQ+] drastically increases the 
induction of [PSI+] (134).  Two other [PSI+] strains are often used in yeast prion studies, Sc4 
and Sc37. These strains were created by in vitro polymerization of Sup35 at either 4°C or 37°C, 
respectively. These two strains are then transformed into [psi-] cells, where they will then seed 
prion formation in vivo (135).  
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Assessing prion strain propagation is one tool used in yeast biology to better understand 
the effects of perturbations in protein folding. One phenotypic assay used to discern [PSI+] prion 
strain formation and propagation involves one of two nonsense mutations, ade1-14 or ade2-1 in 
the adenine biosynthetic pathway (37, 136). This will be further explained in Chapter 2 but, 
overall, this assay allows for [PSI+] colonies to appear white in color and grow on media lacking 
adenine, whilst [psi-] are red and unable to grow without adenine. The use of this assay allows 
for a phenotypic readout of prion propagation and the extent of nonsense suppression in yeast 
due to the presence of [PSI+]. 
1.4.3 The yeast prion [RNQ+] 
Rnq1 is the protein determinant which forms the [RNQ+] prion (137). [RNQ+] prions, 
were originally identified as the [PIN+] element, for [PSI+] inducible (134, 138). Rnq1 was 
found to be a prion protein through yeast proteome analysis, due to its similar sequence of 
glutamine and asparagine (Q/N)-rich prion-forming domains as that of Sup35. The Rnq1 protein 
has four QN-rich stretches within its prion domain, one of which was needed to successfully 
propagate some but not all [RNQ+] variants (137). Interestingly, although [RNQ+] promotes de 
novo formation of [PSI+], once [PSI+] has formed, both prions can propagate independently 
(139). This is why [RNQ+] cells convert to [PSI+] at a higher frequency than [rnq-] (134). It has 
also been reported that [RNQ+] is required for the formation of [URE3] (134, 140). 
Multiple [RNQ+] prion strains, or variants, exist such as: “s.d. low”, “s.d. medium”, “s.d. 
high”, “m.d. low”, “m.d. medium” and, “m.d. high” (137). Unlike [PSI+] strains, which are 
defined by the level of nonsense suppression, [RNQ+] strains are defined by the rate at which 
they promote [PSI+]. Moreover, [RNQ+] strains are classified by their aggregation pattern as 
observed during fluorescent microscopy, when GFP-tagged. For example, single dot (s.d.) 
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[RNQ+] strains will have one focus of fluorescent whilst multi dot (m.d.) [RNQ+] will have 
multiple fluorescent foci (141). As previously mentioned, Sis1 is required for [RNQ+] 
propagation. Moreover, the G/F-rich domain is of upmost importance for the propagation of 
[RNQ+], as deletion of this region completely abolished prion propagation. Although, Sis1∆G/F 
can still bind substrates and stimulate Hsp70s ATPase activity (100). Of note, Rnq1 
overexpression in [RNQ+] cells results in a gain-of-function toxicity which can be rescued by 
Sis1 overexpression (142).  
The presence of [RNQ+] can be assessed biochemically through boiled gel assays, 
solubility and well trap assays as well as through the use of imaging of fluorescent foci when 
Rnq1 is fused to a GFP tag. Moreover, there are [RNQ+] Reporter Protein assays (RRP) which 
utilize a system similar to the [PSI+] colorimetric readout (143).  The following section (1.4.4) 
will delve deeper into the molecular chaperone machinery required for the propagation of S. 
cerevisiae prions, including [RNQ+] and [PSI+]. 
1.4.4 The Molecular Chaperone Machinery: Required for Prion Propagation 
Molecular chaperones are required for the propagation of all yeast prions. Interestingly, 
the diverse molecular chaperone system that is needed to promote prion propagation is also 
required for the protection of yeast from stress and disaggregating misfolded proteins (78). 
Specifically, the first demonstration of chaperones being required for prion propagation was 
established when the propagation of [PSI+] was shown to require the chaperone Hsp104 in yeast 
(54). Since then, many studies have focused on understanding the intricacies of the molecular 
chaperone system and prion propagation in yeast.  
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Overall, it has been found that the molecular chaperones J-domain proteins and Hsp70s 
deliver aggregates to the Hsp104 disaggregase for both resolubilization and this process is 
required for prion propagation (Figure 1.5) (144, 145). For this to happen, the J-domain 
protein/Hsp70 complex will bind to an aggregated substrate and then bind to Hsp104. The 
disaggregase then extracts and fragments protein molecules from the amyloid chain. Due to the 
highly ordered nature of prion aggregates, propagons are created by the fragmentation process. 
Propagons continue propagating the prion and are then passed on to daughter cells during cell 
division. Fragmentation of the amyloids is necessary for prion propagation, without this process 
propagons would not be created, leading to dilution of the prion and loss of the ability to pass the 
structure to daughter cells during cell division (52). 
Interestingly, J-domain proteins impact prion propagation differentially depending on the 
client. For example, changes in Hsp40 levels, functionality, and localization affects [PSI+] and 
[URE3] differently (103, 117, 146). Furthermore, [URE3], as opposed to [PSI+], is dependent on 
the G-rich domains of Sis1 and deletion of the Sis1 terminal domain destabilizes both prions, 
enhancing prion-dependent toxicity (147). Interestingly, overexpression of the J-domain appears 
to cure [URE3] (148).  With regard to Sis1, it appears that the chaperone is important for 
Hsp104-mediated curing of the [PSI+] prion as overexpression of Sis1 facilitates curing of 
[PSI+] by excess Hsp104 (149). In the context of Hsp70 and prion propagation, it is known that 
Ssa chaperones can all bind to Sup35 and help propagate [PSI+] (72). Indeed, the Ssa family of 
chaperones are the most abundant proteins to co-IP with Sup35. Interestingly, mutations or 
deletions in Ssa1 or Ssa2 destabilizes or even cures some [PSI+] strains (113, 114). It is now 
better understood that different chaperones and prions interact with certain specificity, 
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highlighting the importance of substrate and conformational specificity for the players involved 
in the Hsp40/Hsp70/Hsp104 machinery.  
1.5 Limb-Girdle Muscle Dystrophy Type 1D (LGMDD1) 
1.5.1 Myopathies 
Myopathies are considered a clinical disorder of skeletal muscle whereby aberrations in 
muscle cell structure and function lead to weakness. In some cases of myopathy, pathology 
extends to cardiac muscle leading to cardiomyopathy (150). The causes of myopathies can be 
primarily classified into two groups: acquired myopathies and inherited myopathies (151). 
Acquired myopathies include inflammatory myopathies, infections, toxic myopathies and 
myopathy associated with systemic diseases. Furthermore, inherited myopathies include 
muscular dystrophy, congenital myopathy, metabolic myopathy and mitochondrial myopathy 
(152). Interestingly, at least 15 chaperones or co-chaperones have been known to underlie 
neuromuscular disorders (Table 1.1). Moreover, oftentimes it appears that these chaperones are 
deeply interconnected within the chaperone and co-chaperone network linked to neuromuscular 
disease (Figure 1.6) (153).  
For inherited myopathies, such as congenital myopathy or muscular dystrophy, current 
treatments are mostly supportive and include physical therapy, occupational therapy and genetic 
counseling. For other myopathies, such as Duchenne muscular dystrophy or mitochondrial 
myopathy, there have been some treatments that show improved strength and muscle bulk (154, 
155). Of relevance to this dissertation we will further discuss a type of muscle dystrophy, known 
as limb girdle muscular dystrophy (LGMD), in the following section. 
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1.5.2 LGMD  
Limb girdle muscular dystrophies (LGMDs) are a group of muscle diseases with a 
frequency ranging from 1 in 15,000-45,000 (156, 157). Initially, diseases that presented certain 
criteria, such as proximal weakness and atrophy, dystrophy of muscle tissue and elevated 
creatine kinase levels, were considered to be LGMDs (158). To date, more than 30 distinct 
subtypes of LGMD have been identified (Table 1.2) (159). Moreover, subtypes of LGMD may 
present a variable extent of cardiomyopathy and/or respiratory muscle weakness (160). 
Dominantly inherited LGMDs are far less common than recessive inherited LGMDs and 
compose 5-10% of all LGMDs (161, 162). Furthermore, due to the significant genetic and 
clinical heterogeneity, varying with severity and age of onset, there are difficulties in diagnosing 
and differing opinions on classification (153). 
LGMDs are classified into two groups: LGMD1 and LGMD2, with the former being 
autosomal dominant and the latter being autosomal recessive (163).  For nomenclature purposes, 
a letter is added in the order of discovery (161). LGMDD1, for example, along with 1F and 1G, 
have all been described in small numbers and in a limited number of families. Typically, onset 
occurs in adulthood with proximal muscle weakness (159). Cardiac and respiratory involvement 
in these subtypes is not yet understood, although patients do present similar features to that of 
patients with myofibrillar myopathies. 
1.5.3 Type 1D LGMD 
 Limb girdle muscle dystrophy type 1D (LGMDD1), at the cellular level, is a disorder 
characterized by protein aggregates and rimmed vacuoles in muscle fibers. This myopathy was 
first described in the late 1960’s as “an unusual form of muscle dystrophy” (164). Since then, 
this definition has been expanded and with the help of advances in sequencing technologies, 
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people with LGMDD1 have been successfully diagnosed and studied in an effort to better 
understand this disease. Throughout the years, the disease has been described as patients often 
presenting with adult-onset progressive muscular dystrophy, which affects proximal muscles 
predominantly. Since then, novel mutations being reported highlight a more diverse and 
heterogeneous phenotype for patients with LGMDD1 (75). For example, phenotypes now 
include childhood-onset, effects on distal muscles, loss of ambulation earlier in life and 
respiratory involvement (165). Moreover, historically, mutations associated with LGMDD1 had 
been linked exclusively to the G/F-rich domain of the mammalian J-domain protein, DNAJB6, 
through a dominant toxic effect (Figure1. 7) (20–23, 165). Recently, colleagues have recently 
identified novel mutations associated with LGMDD1 in the same protein, but within the J-
domain instead (166). 
To further study the effects of these mutations on adequate chaperone function and 
pathology, studies have been performed using various models, such as mouse models, 
mammalian cell and tissue cultures, yeast prion models and extensive characterization of patient 
tissue and imagery (167). From these studies we know pathogenesis of LGMDD1 is mediated by 
defective chaperone function (117). Furthermore, the molecular chaperone DNAJB6 has been 
shown to have a role in aggregate disaggregation, and indeed, in patients presenting with 
mutations in DNJAB6, this anti-aggregation property is reduced (75, 153, 166). Studies have 
shown how mutations increase DNAJB6’s half-life, thus extending the effect to the WT protein 
and reducing its protective anti-aggregation effect (75). While we know DNAJB6 has an anti-
aggregation effect, DNAJB6 has no clear mammalian client protein and has been proposed to 
promiscuously associate with multiple proteins. 
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As we continue to better understand these mutations and the pathology associated with 
them, our understanding of LGMDD1 and the spectrum of DNAJB6-related phenotypes have 
widened.  In the subsequent sections we will further describe the pathology associated with 
specific mutations in either the G/F-rich or J-domain of DNAJB6. 
1.5.4 LGMDD1-associated mutations in the G/F-domain 
Historically, LGMDD1-associated mutations have been thought to all be localized to the 
G/F-rich domain of the class B mammalian J-domain protein DnaJB6. From the late 1990’s until 
the year 2019, all mutations linked to LGMDD1 have been found in this domain. Overall, most 
mutations found in this domain have shown an LGMD phenotype, although a subset of these are 
associated with a more distal phenotype. There are a multitude of mutations reported in the 
DNAJB6 G/F-rich region (often affecting the same codon) that are associated to LGMDD1 
pathogenesis (Table 1.3) (153).  
Assessment of the different pathological presentations in patients with LGMDD1 
indicates variability depending on the particular mutation the patient presents and inter- and 
intra-familial variability (22, 165, 168–171). While most mutations confer a classical LGMD 
phenotype, some mutations appear to present an earlier onset with severe pathology (168, 170), 
while others present as having a more distal onset (21, 166, 168). Nonetheless, it appears that all 
mutations result in similar protein accumulations and aggregation of Z-disk proteins (22, 93). 
Such an effect has also been demonstrated using mouse models expressing DNAJB6-F93L (93). 
Studies in both human and mouse muscle have shown protein accumulations that include 
structural proteins, RNA-binding stress-granule proteins, chaperones and co-chaperones. Among 
other pathological presentations, difficulty swallowing (dysphagia) has often been reported 
(174). Respiratory involvement requiring mechanical ventilation is unusual for LGMDD1, 
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although patients with more severe mutations, such as F91I and F91L, have needed such medical 
intervention (174). Interestingly, patients with the mutation F91V does not seem to have 
respiratory symptoms and show milder progression and overall phenotype (175). 
Several studies have focused on the pathomechanism of DNAJB6 mutations and have 
identified functional consequences for such mutations (171). Most strikingly, all mutations in the 
G/F-rich domain affect DNAJB6’s anti-polyQ aggregation properties, while only F89I, F93L and 
P96R enhanced the formation of TDP-43 aggregates and impaired their clearance following heat 
shock (153). Of note, F89I and P96R have also shown a defect in propagation of the yeast prions 
[PSI+] and [RNQ+] (93). Furthermore, there is evidence for pathogenesis depending on a 
dominant toxic effect, in addition to mutant DNAJB6 having a decreased turnover rate (117). 
1.5.5 LGMDD1-associated mutations in the J-domain 
The first two confirmed pathogenic mutations in the J-domain of DNAJB6 were recently 
identified. Both of these mutations, A50V and E54A, are found in the alpha3 helix of the J-
domain (22, 93). Although its pathogenesis is not yet confirmed, another mutation, N56L, has 
been  associated with LGMDD1. Phenotypically, mutations in the J-domain appear to have a 
more distal presentation with A50V being distal and E54A presenting as proximo-distal. Both 
confirmed J-domain mutations show altered PolyQ and TDP-43 anti-aggregation, similar to the 
G/F domain mutations (166). Structure analysis through protein threading has allowed us and 
others to hypothesize that these J-domain mutations are in direct contact with the alpha5 region 
of the G/F-rich domain (166). The work herein will further highlight these findings but, as a 
general takeaway, the current hypothesis is that mutations in the J-domain interfere with the 
structural intramolecular integrity between the J- and G/F-domains that is necessary for adequate 
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chaperone function and client processing. LGDD1 mutations in the J-domain will be further 
examined in Chapter 2. 
1.6 Objective, Results, and Significance of Thesis 
The objective of this work is to assess the effect of disease-associated mutations on the 
adequate function of J-domain protein co-chaperones and to identify potential therapeutic 
approaches. Based on previous work we knew that mutations in the G/F-rich domain of the 
mammalian J-domain protein DnaJB6 were associated with Limb girdle muscular dystrophy type 
1D. Previous work from our lab has shown that these multiple mutations differentially affect J-
domain protein client processing in a manner that is conformation and client specific. Recent 
work from our collaborators has identified novel mutations associated with LGMDD1 in the J-
domain of DNAJB6b. These findings have guided our work looking into how LGMDD1-
associated mutations in the J-domain of this protein may affect chaperone function, substrate 
processing and specificity.  
We have found that the various mutations in the J domain of the homologous Class B J-
domain protein Sis1 do alter substrate processing in a client and conformation specific manner. 
We hypothesize that it is the altered protein structure due to mutations in either the G/F domain 
or in the J domain , associated with LGMDD1, that is responsible for the defect in substrate 
processing. In addition, we found novel evidence that while a mutation in a J-domain protein 
affects its steady-state levels, this effect is rescued by a potential interaction with a client protein. 
Furthermore, we have identified second-site suppressor mutations that rescued the growth defect 
identified by expression of a disease-associated mutant in the G/F-rich domain. We have created 
yeast strains whereby combinatorial mutations and second-site suppressors are expressed with 
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the hope of identifying suppressors which could revert the defective processing of the mutated 
chaperone. 
Mainly, this dissertation considers the effect of disease-associated mutagenesis on J-domain 
protein function. Chapter two explores the effect of novel myopathy-associated mutations in the 
DNAJB6 J-domain where I show that, similar to myopathy-associated G/F domain mutations, 
these novel mutants have client specificity and modulate J-domain protein chaperone function. 
Chapter three explores the possibility of using second-site suppressors to rescue aberrant J-
domain protein function due to disease-associated mutations. Overall, we created strains in 
[RNQ+] and [PSI+] expressing homologous second-site suppressors in the SDSS chimera and 
found no viability defect when the second-site suppressors were expressed. Finally, chapter four 
focuses on the broader implications of this work and the future directions that will provide 
insight into the aberrant function of mutated J-domain protein chaperones, how mutations in the 
J-domain affect client processing, and how therapeutic avenues may arise from the use of 
second-site suppressors. 
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1.7 Figures 
 
Figure 1.1: Pathogenesis of DNAJ mutations. Illustration adapted (166); the image 
demonstrates the tissues and organs affected by mutations in DNAJ family proteins. The color of 
the tissue indicates the system or organ affected: cyan indicates the nervous system, purple 
indicates eyes, blue indicates the nose, beige highlights the lungs, red indicates the heart and 
blood vessels, the liver is indicated by a dark pink color, the kidneys are indicated by the color 
green, muscles are orange, the reproductive system is brown in color and the bones are indicated 
by the color grey.  
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Figure 1.2: Functional reaction cycle of Hsp70. Adapted from Kim et al 2013 (28); ATP 
binding to the NBD stabilizes the open state of Hsp70, facilitating the binding of substrate 
protein recruited to Hsp70 by J-domain protein cochaperone. J-domain proteins stimulates ATP 
hydrolysis, resulting in the closing of the Hsp70 SBD α-helical lid over the bound substrate 
peptide. NEFs stimulate the release of ADP from the NBD, and ATP binding causes substrate 
release. 
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Figure 1.3: J-domain protein classes and domain structure. Modified from Rosenzweig 2019 
(30). General domain organization of class A (top), class B (middle) and class C (bottom) J-
domain proteins with a cartoon representation showing the four- helical structure of the J- 
domain and highlighting the location of the conserved HPD motif residues. 
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Figure 1.4. DNAJB6 Isoforms, mutations and protein structure of J-domain. Adapted (60); 
(A) A schematic view of the DNAJB6 protein, with the various domains, and the alternatively 
spliced C-terminal parts of the “a” and “b” isoforms indicated. The inset shows the sequence of 
the (G/F) domain, with myopathy-causing mutations indicated by the pink arrows. (B) Protein 
structure of the J (orange) and G/F (green) domains, the residues harboring disease mutations are 
shown. Structure from Protein Data Bank ID 6U3R. 
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Figure 1.5: The role of chaperones in the propagation of the Sup35 prion. Adapted (153); 
(A) Polymer fragmentation and propagon formation with normal Hsp104, Hsp70, and J-domain 
protein levels. (B) Impairment of prion propagation in the absence of Hsp104. (C) Impairment of 
prion propagation at high levels of Hsp104. Image indicates two models by which this may 
occur. Red squares indicate Sup35N (PrD) in prion form; red lines indicate Sup35M linker and 
Sup35N in a misfolded intermediate form; red spiral lines indicate the Sup35NM region in a 
non-prion form; red circles indicate the globular Sup35C domain. 
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Table 1.1. Chaperone genes known to underlie neuromuscular disorders. Adapted from 
Sarparanta 2020 (52). 
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Figure 1.6. Interaction network of chaperones and co-chaperones associated with 
neuromuscular disorders. Adapted from Sarparanta 2020 (153). 
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Table 1.2. LGMD subtypes, genes and protein functions. Adapted (153); This table represents 
the different LGMD subtypes, genes and protein functions. 
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Table 1.3:  DNAJB6 mutations causing neuromuscular disease. Adapted (159); This table 
shows the cDNA changes identified and confirmed to be associated with LGMDD1 in either the 
J- or G/F-domain of DNAJB6, this includes the associated protein change and phenotype of 
disease. 
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Figure 1.7: Suggested pathomechanism of DNAJB6 mutations. Adapted (153). (A) Top: The 
suggested function of DNAJB6 in the HSP40/70 cycle: (1) Client binding by DNAJB6. (2) 
HSP70 binding to J-Domain protein. (3) ATP hydrolysis and client transfer to HSP70. (4) 
Displacement of HSP70 by the G/F domain. Bottom: A model for the effect of myopathy 
mutations. The mutations interfere with the interaction between the J and G/F domains, leading 
to uncontrolled interaction with HSP70. (B) Possible parallel downstream pathways leading from 
DNAJB6 mutations to muscle disease. 
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2.1 Abstract 
The misfolding and aggregation of proteins is often implicated in the development and 
progression of degenerative diseases. Heat shock proteins (HSPs), such as the ubiquitously 
expressed Type II Hsp40 molecular chaperone, DNAJB6, assist in protein folding and 
disaggregation. Historically, mutations within the DNAJB6 G/F domain have been associated 
with Limb-Girdle Muscular Dystrophy type 1D, now referred to as LGMDD1, a dominantly 
inherited degenerative disease. Recently, novel mutations within the J domain of DNAJB6 have 
been reported in patients with LGMDD1. Since novel myopathy-causing mutations in the Hsp40 
J domain have yet to be characterized and both the function of DNAJB6 in skeletal muscle and 
the clients of this chaperone are unknown, we set out to assess the effect of these mutations on 
chaperone function using the genetically tractable yeast system. The essential yeast Type II 
Hsp40, Sis1, is homologous to DNAJB6 and is involved in the propagation of yeast prions. 
Using phenotypic, biochemical, and functional assays we found that homologous mutations in 
the Sis1 J domain differentially alter the processing of specific yeast prion strains, as well as a 
non-prion substrate. These data suggest that the newly-identified mutations in the J domain of 
DNAJB6 cause aberrant chaperone function that leads to the pathogenesis in LGMDD1. 
2.2  Introduction 
Molecular chaperones preserve protein homeostasis (1). A deficient chaperone network 
may lead to protein misfolding and aggregation often associated with protein conformational 
disorders such as Alzheimer’s Disease, Charcot-Marie-Tooth disease, distal hereditary motor 
neuropathies, and Limb Girdle Muscular Dystrophy, among others (2, 3). Limb Girdle Muscular 
Dystrophy type 1D (LGMD1D), more recently termed LGMDD1 (4), is a disease characterized 
by proximal muscle weakness with moderate progression mediated by defective chaperone 
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function (5). Historically, dominantly inherited disease-associated mutations in the type II Hsp40 
co-chaperone DNAJB6 have been found within a 12 amino acid region known as the G/F 
domain (6–11). Recently, three novel pathogenic mutations associated with LGMDD1 have been 
identified within the J domain of DNAJB6 (12, 13). 
Since the heat shock response is highly conserved from yeast to mammals, we used a 
yeast model system to study these disease-associated mutations (14–16). The essential yeast 
Type II Hsp40, Sis1, is homologous to DNAJB6 and plays an important role in yeast for the 
propagation of two prions, [RNQ+] and [PSI+] (17–22). Prions in yeast are epigenetic elements 
that form when the prion proteins form amyloid aggregates. These prion protein aggregates are 
propagated by fragmentation into propagons, which are then passed on to progeny during mitosis 
(14). Somewhat counterintuitively, chaperones not only promote prion propagation in yeast, but 
are essential for it (14, 23–26). At the heart of this chaperone-mediated process is the Hsp40 
Sis1, with the interaction between Hsp40 and Hsp70 chaperones being crucial for prion 
propagation in yeast (24, 27–32). When chaperone function is defective, prion propagation is 
impaired (17, 33–36). Thus, the loss of prion propagation provides a read-out for chaperone 
dysfunction in yeast. 
Homologous LGMDD1-associated mutations of the DNAJB6 G/F domain impair the 
propagation of various yeast prion strains when expressed in Sis1 (37). We were inspired by this 
model to assess the effect of homologous J domain mutants in Sis1 on chaperone function. 
Fortunately, the yeast model system allows for a wide array of phenotypic, biochemical, and 
functional assays to assess the effect of these mutations on chaperone function (14, 38). As such, 
we assessed the ability of the disease-associated mutant chaperone to process two specific clients 
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of Sis1, Sup35 and Rnq1, which form the prion elements [PSI+] and [RNQ+], respectively. In 
addition, we performed functional assays with a non-prion client of the yeast chaperone 
machinery, firefly luciferase (FFL) (39). In conjunction, these assays elucidated nuances in client 
processing due to disease-associated mutations in a manner that would not be possible by 
assessing a single client protein or using a limited number of assays. 
Here, we present evidence that disease-associated mutations in the J domain cause 
functional defects that differentially impair processing of native proteins in a client and 
conformer specific manner.  Our work suggests that mutations in the J domain are responsible 
for altered protein processing and, potentially, disease pathogenesis. 
2.3  Results 
2.3.1 Homologous mutations in the Sis1 J domain are conserved and 
potentially alter J domain and G/F domain interaction.  
Recently, novel mutations located within a 7 amino acid region of the DNAJB6 J domain 
have been reported to cause dominant distal myopathy (12, 13). These variants were identified in 
five different families presenting with both distal and proximal muscle weakness. Initial studies 
examined these variants in patient tissue and cell culture studies in an attempt to elucidate 
whether these mutations lead to functional defects in DNAJB6's anti-aggregation activity. From 
these studies, the recently identified DNAJB6 variants DNAJB6-A50V, DNAJB6-E54A and 
DNAJB6-S57L have been categorized as pathogenic, likely pathogenic, and variant of unknown 
significance, respectively (12). 
 To further examine the effect of these disease-associated variants on myopathy, we 
performed protein threading to identify homologous mutations in the yeast Hsp40 Sis1. Our 
comparative modeling identified homologous J domain mutations in Sis1 to be Sis1-S49V 
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(homologous to DNAJB6-A50V), Sis1-E53A (homologous to DNAJB6-E54A), and Sis1-N56L 
(homologous to DNAJB6-S57L) (Figure 2.1A). In addition, our structural model recapitulates 
the observation that mutations in the J domain have the potential to disrupt important 
intramolecular interactions previously shown to stabilize the interface between the G/F and J 
domains (Figure 2.1B) (12, 21). 
2.3.2 Homologous mutations in the J domain of Sis1 differentially impair 
[PSI+] prion propagation.  
 To assess the implications of these disease-causing variants on chaperone function, we 
turned to prion propagation models in yeast. Such models have been used extensively to study 
chaperones and understand the deleterious effects of disease-associated mutations on protein 
folding (40–46). In yeast, prions are naturally occurring, self-propagating protein structures that 
require chaperone networks for their efficient propagation (14). Defects in chaperone function 
disrupt this process and, therefore, prion propagation (27, 33–36, 47, 48). In order to ask whether 
these disease variants disrupt client processing, we studied two known Sis1 substrates: the 
translation termination factor Sup35, which forms the [PSI+] prion, and Rnq1, which forms the 
[RNQ+] prion (14, 29). 
In an effort to understand the effect of homologous J domain mutations on [PSI+] prion 
propagation we performed experiments utilizing strains harboring the ade1-14 allele that has a 
premature stop codon in the ADE1 open reading frame (14). When Sup35 misfolds and 
aggregates in the [PSI+] state, nonsense suppression of the premature stop codon in ade1-14 
occurs and the adenine biosynthesis pathway is completed. Thus, [PSI+] colonies are white in 
color and can grow on media lacking adenine. Conversely, if cells are [psi-], adenine 
biosynthesis is incomplete, resulting in cells that are unable to grow in media lacking adenine 
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and an accumulation of red pigment in cells grown on rich media. This colorimetric phenotypic 
assay has been utilized to demonstrate the effect of LGMDD1-causing G/F domain mutations on 
[PSI+] propagation (37). Here, we make use of four different [PSI+] strains (weak, strong, Sc37, 
and Sc4) (49, 50). Each prion strain is a different self-propagating conformation of the same 
protein sequence and they are differentiated by the strength of the nonsense suppression 
phenotype and stability of their mitotic inheritance (49, 51–53). Yeast containing ade1-14 that 
propagate stronger [PSI+] strains (strong and Sc4) display higher nonsense suppression and are 
lighter in color. Yeast propagating weaker [PSI+] strains (weak and Sc37) are darker in color due 
to decreased nonsense suppression (better translation termination). Sis1 is required for yeast 
viability (54). Therefore, to perform these experiments, we used sis1∆ yeast (covered by a 
plasmid expressing Sis1) propagating different [PSI+] strains (weak, strong, Sc37, and Sc4) and 
replaced SIS1 with homologous LGMDD1 mutant SIS1 constructs or wild-type SIS1 (as a 
control) (Figure 2.2A).  In doing so, we observed viability was not affected in these strains 
expressing the mutants. 
Interestingly, we found that expression of Sis1-S49V in the weak [PSI+] strain, but not 
the Sc37 [PSI+] strain, altered the weak strain phenotype, as indicated by the lighter color on rich 
media and robust growth in selective media as compared to wild-type (Figure 2.2A). In 
comparison to the other J domain mutants, the stronger nonsense suppression phenotype we 
observed is unique to expression of Sis1-S49V in the weak [PSI+] strain. This suggests altered 
processing of Sup35 by Sis1-S49V occurs with conformational specificity. We questioned 
whether expression of Sis1-S49V could have altered the conformation of Sup35 in weak [PSI+] 
in a manner that leads to the propagation of a strong [PSI+] strain. Intrigued by this result, we 
introduced pRS316-Sis1 (wildtype) to this strain and re-assessed its [PSI+] phenotype 
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(Supporting Figure S1). We found this reverted the phenotype and was comparable to wild-type 
controls, suggesting that Sis1-S49V expression does not alter the [PSI+] strain. Previous work 
demonstrated that a shortage of cytosolic Sis1 may lead to more efficient transmission of 
propagons to daughter cells thus “strengthening” the prion phenotype (55). Thus, we hypothesize 
this may occur when Sis1-S49V is expressed in a weak [PSI+] strain. 
This assay also showed that the expression of either Sis1-E53A or Sis1-N56L altered the 
propagation of the weaker [PSI+] strains (weak and Sc37), albeit in a different manner and to 
varying degrees. This is indicated by the phenotypic change towards a red color (less nonsense 
suppression) on rich media and lack of growth on media lacking adenine (Figure 2.2A). 
Similarly, when we introduced a wild type copy of SIS1 to these phenotypically red strains, we 
identified a partial rescue of the weak [PSI+] phenotype (Supporting Figure S1) indicating these 
Sis1 mutants, although phenotypically [psi-], result in propagation of cryptic [PSI+] propagons 
(56).  
Complementarily, we used this assay quantitatively by phenotypically scoring large 
numbers of colonies on rich media spread plates (Figure 2.2B). This assay allows for a more 
detailed understanding of the variability in [PSI+] propagation. We scored colony color as light 
pink (strong [PSI+]), dark pink (weak [PSI+]) or red (very weak [PSI+] or [psi-]) in yeast 
expressing wild type Sis1 or the homologous LGMDD1 mutants. Indeed, through this assay we 
found that the expression of these mutants phenotypically altered prion propagation and 
identified a phenotypic variation that was not previously appreciated in the spotting assay. We 
observed a wider range of phenotypic variation in the weaker strains than in the stronger [PSI+] 
strains, which rarely convert to a weaker phenotype (57, 58). However, an increase in darker 
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pink colonies was observed when Sis1-S49V and Sis1-N56L were expressed in the stronger 
[PSI+] strains. Similar results were observed when Sis1-E53A and Sis1-N56L were expressed in 
the Sc4 [PSI+] strain. 
To further explore these results with respect to the solubility of the prion protein, we 
performed boiled gel assays to examine the relative levels of aggregated and monomeric Sup35. 
This assay consists of loading unboiled samples onto an SDS-PAGE gel. By doing so, non-
denatured aggregates are too large to enter the resolving gel while monomeric Sup35 readily 
enters the gel due to its size and lack of aggregation. Halfway through electrophoresis, the gel 
itself is boiled and then run again, which allows previously aggregated protein to enter the 
resolving gel. The boiled gel assay provides a clear separation of monomeric and aggregated 
species of Sup35 and is easily detected through subsequent western blots (59). In order to 
examine the distribution of Sup35 between the aggregated and monomeric forms, we grew 
cultures from colonies representative of the phenotypic distribution observed in our spread plate 
assay.  
Expressing homologous J domain mutations in the strong or Sc4 [PSI+] strains did not 
alter Sup35 distribution nor phenotype significantly (Figure 2.2C). Interestingly, the distribution 
of Sup35 between monomer and aggregate does not always correlate to phenotype in the weaker 
[PSI+] strains (many replicates of these assays were performed to verify reproducibility).  Of 
note, we previously described a chaperone mutant that demonstrated differences in the ability to 
relate SDS-resistant or small protein aggregates to phenotype (56).  Moreover, we found that 
expressing Sis1-S49V in the weak [PSI+] strain led to Sup35 being found mostly in the 
aggregated state (Figure 2.2C), coinciding with our phenotypic assay. With regards to expression 
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of Sis1-E53A in the weak [PSI+] strain, we were surprised to find little Sup35 in the monomeric 
fraction, while the expression of Sis1-N56L results in most of the Sup35 in the monomeric 
fraction. Interestingly, expressing Sis1-S49V, Sis1-E53A or Sis1-N56L in the Sc37 [PSI+] strain 
showed a marked increase in monomeric Sup35, as compared to wild-type controls, while 
maintaining a modest level of aggregated Sup35. Thus, there are differences with respect to the 
interaction between the Sis1 mutants and Sup35 in the weaker [PSI+] strains and how propagons 
and large aggregates correlate to phenotype.  
2.3.3 Homologous mutations in the J domain of Sis1 differentially impair 
[RNQ+] prion propagation.  
We then asked whether mutations in the Sis1 J domain would also affect another known 
client of Sis1, the [RNQ+] prion. In a manner similar to that of the previous experiments, we 
utilized various [RNQ+] prion strains (rnq-, low, and very high) and expressed each of our Sis1 
mutants. Here, we observed reduced growth when Sis1-S49V was expressed in [psi-] strains that 
we did not observe in the same yeast strains harboring the [PSI+] prion. Thus, we performed 
spottings (using 5-fold serial dilutions) and confirmed that expression of Sis1-S49V, but not 
Sis1-E53A or Sis1-N56L, resulted in a growth defect (Figure 2.3A). This effect was only 
observed when wild-type Sis1 was removed through plasmid shuffle and occurred when Sis1-
S49V was expressed in either [RNQ+] or [rnq-] strains. This indicated the defect in growth was 
independent of [RNQ+] and it was possibly impacted by the loss of [PSI+]. Because Sis1 is 
essential for yeast growth, mutations in Sis1 have been shown to affect viability (20, 54, 60, 61). 
 Unlike the nonsense suppression assay that discerns [PSI+] strains, strains of the [RNQ+] 
prion are characterized by the rate at which they induce the formation of [PSI+], ranging from 
low to very high rates (62–65). Therefore, we performed two different biochemical assays to 
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assess [RNQ+] propagation. First, we performed a sedimentation assay (59) which consists of 
separating the soluble and insoluble protein fractions using ultracentrifugation to assay the 
relative solubility of Rnq1. These fractions are subjected to SDS-Page and probed with an 
antibody specific to Rnq1. We performed this assay using two [RNQ+] strains, low [RNQ+] and 
v.h. [RNQ+]. Using this assay, we identified a defect in [RNQ+] propagation when Sis1-S49V is 
expressed in both low [RNQ+] and v.h. [RNQ+] strains (Figure 2.3B). In comparison, there is only 
a slight change in Rnq1 solubility when Sis1-E53A or Sis1-N56L are expressed, indicating that J 
domain variants differentially impair processing of client conformers, albeit not completely. 
 Furthermore, in an effort to elucidate whether Rnq1 aggregate size or SDS resistance was 
altered by expression of the mutants, we performed a semi-denaturing detergent agarose gel 
electrophoresis (SDD-AGE) (Figure 2.3C). This assay allows for the visualization of SDS-
resistant aggregates such as aggregated prion conformers (66). Strikingly, we observed a 
dramatic loss of SDS-resistant Rnq1 aggregates in the low and v.h. [RNQ+] strains when Sis1-
S49V was expressed. We also observed a slight reduction in SDS-resistant Rnq1 aggregates in 
low [RNQ+] strains expressing Sis1-E53A, while low [RNQ+] strains expressing Sis1-N56L 
appeared unaffected. In addition, v.h. [RNQ+] strains expressing Sis1-E53A or Sis1-N56L 
showed a decreased in SDS-resistant Rnq1 aggregates. Altogether, these biochemical assays 
present varying degrees of altered [RNQ+] propagation that occur in a conformer-specific manner 
when  disease-associated J domain mutants are expressed in these strains. 
2.3.4 Disruption in prion propagation is due to a defect in substrate refolding.  
 We observed different degrees of alteration in prion propagation due to the expression of 
the homologous LGMDD1 mutations in the J domain, which vary depending on the client and its 
conformation. To further understand the effect of these disease-associated mutations, we 
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assessed how they impact protein folding of a non-prion substrate in vivo. Thus, we utilized the 
well-established firefly luciferase (FFL) refolding assay (67, 68) (Figure 2.4). FFL is a non-prion 
substrate of the Hsp40/Hsp70/Hsp104 chaperone machinery and is denatured in cells by heat 
shock.  When FFL misfolds and aggregates it requires the Hsp40/Hsp70/Hsp104 chaperone 
machinery to efficiently refold. Since Hsp104 is required for efficient refolding of FFL, we used 
a hsp104∆ strain expressing FFL as a negative control.  We observed a significant defect in FFL 
refolding when Sis1-S49V was expressed in either a [PSI+] [RNQ+] (Figure 2.4) or [psi-] [rnq-] 
strain (Supporting Figure S2A), but not when other J domain variants are expressed. We 
subjected other known G/F domain mutants expressed in a chimeric protein where the G/F 
domain of Sis1 is replaced by that of DNAJB6, referred to as SDSS (37), to this assay and saw 
no significant differences in luciferase refolding as compared to wild type (Supporting Figure 
S2B). Hence, these results highlight the importance of substrate recognition – both with the 
client itself, as well as conformer specificity. Most importantly, these findings emphasize the 
distinction of assessing native chaperone clients as these mutants displayed varying degrees of 
altered prion propagation in our assays. Given this specificity, care should be taken when using 
certain assays, or a limited number of them, when trying to understand and confirm whether a 
potentially pathogenic chaperone variant is disease-causing or not. 
2.3.5 Stability of a mutated Hsp40 chaperone is rescued by expression of the 
[PSI+] prion.  
 While assessing the effect of the J domain LGMDD1 mutations on [RNQ+] propagation 
we identified a growth defect that only occurred with expression of the Sis1-S49V variant 
(Figure 2.3A). Interestingly, we observed this defect when Sis1-S49V was expressed in [RNQ+] 
[psi-] strains, but not when expressed in [PSI+] strains (Figure 2.2A and Figure 2.3A). Because 
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SIS1 is essential (20, 54, 60, 61), we were curious whether this growth defect was due to any 
change in steady-state expression levels. We assessed steady state Sis1 levels by western blot 
and found a 40-60% decrease in the level of Sis1-S49V in various [RNQ+] and [rnq-] strains 
(Figure 2.5A). We hypothesize that this decrease in steady-state levels is responsible for the 
growth defect.  
 To confirm this decrease is due to a lack of [PSI+] presence, we set out to recapitulate this 
phenomenon by curing [PSI+] strains of its prion form. Curing of [PSI+] was performed by 
growth on media containing guanidine hydrochloride (GdHCl), which inactivates the ATPase 
activity of Hsp104 and hinders the replication of [PSI+] seeds (69). After curing both a strong  
[PSI+] and a Sc37 [PSI+] strain (each expressing Sis1-S49V) we identified a significant decrease 
in Sis1 steady-state levels, and this was not observed with expression of wild type Sis1 nor the 
other LGMDD1 J domain variants (Figure 2.5B). The decrease in steady-state levels 
recapitulates what we observed in [psi-] strains expressing Sis1-S49V (Figure 2.5A). This 
striking result suggests the Sis1 client, Sup35, in its aggregated and [PSI+]-propagating form, 
interacts with this particular Hsp40 mutant in a way that stabilizes the steady-state level of Sis1-
S49V. Of note, this decrease in Sis1 steady-state levels has not been observed in the context of 
LGMDD1-associated mutations found in the G/F domain. This interesting finding is the first 
known instance wherein a potentially unstable mutant chaperone is stabilized by the presence of 
a specific client protein in its aggregated form. 
2.4 Discussion 
 LGMDD1 is a myopathy historically characterized by mutations within the G/F domain 
of the chaperone DNAJB6 (6–9, 11). Here we used the yeast model system, a homologous 
chaperone, and native chaperone clients to demonstrate that recently reported mutations in the J 
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domain of DNAJB6 alter canonical chaperone function. Specifically, expression of homologous 
disease-associated mutations in the yeast Hsp40, Sis1, identified defects in prion propagation to 
varying degrees depending on the disease-associated variant, the client protein and its 
conformation, as well as a significant defect in refolding of a non-prion client protein. We 
conclude these mutations in the J domain of Sis1 lead to aberrant chaperone function, altered 
protein homeostasis, and potentially drive a variety of defects in chaperone machinery which 
may contribute to pathogenesis. 
The function and interaction of the various Hsp40 domains has been a topic of interest for 
many years (20, 21, 70–75). Surprisingly, colleagues identified LGMDD1 patients with novel 
variants in the J domain of DNAJB6, a disease previously characterized by mutations in the G/F 
domain (12, 13). As previously mentioned, LGMDD1 disease-associated mutations in the G/F 
domain have been found to impair the processing of specific client conformers. These findings 
highlighted the G/F domain as having an important role in substrate regulation and conformer 
selectivity (37). By contrast, the J domain of Sis1 has a known role in regulating Hsp70 ATPase 
activity (76).  
Here we demonstrate a novel finding by which disease-associated missense mutations in 
the J domain of an Hsp40 result in the chaperone having client and conformer specificity. 
Strikingly, this fits with previous structural studies which have highlighted the importance of the 
intramolecular interaction between the J and G/F domains (21). Specifically, a particular amino 
acid, E50, in the Sis1 J domain has been shown to interact with the EEVD(HSP70) motif, an 
interaction required for both chaperones to partner in protein refolding (21). Moreover, this key 
amino acid (E50) forms a salt bridge with R73 which is found in the Sis1 G/F domain. We and 
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others (12, 21) believe this interaction is crucial and of functional importance for the stability and 
interaction between both domains and, ultimately, the interaction between Hsp40 and Hsp70.  
In the context of the LGMDD1-associated mutants found in the J domain, all variants 
appear to affect prion propagation to varying degrees depending on client and conformation 
specificity. Notably, the homologous Sis1-S49V variant appears to have the most deleterious 
effect on the chaperone machinery and its function, probably due to its proximity to the E50:R73 
salt bridge. This would also explain why only Sis1-S49V presented with defective substrate 
refolding in our luciferase refolding assay. Overall, we hypothesize that the steric hindrance 
caused by these missense mutations may obstruct the intramolecular interaction or 
communication between the J and G/F domains. Moreover, these findings support the idea that it 
may be the interaction between these two domains that is crucial for the specificity and 
processing of Hsp40 client proteins. 
By assessing the propagation of various Sis1 clients, we found that there are differences 
in prion propagation, but that propagation is not completely abolished by expression of these 
mutants. When compared to LGMDD1-associated mutations in the G/F domain, for example, we 
observe variants in the G/F domain to have a stronger effect on prion propagation in certain 
assays, oftentimes demonstrating complete loss of prion propagation (37). As such, although 
these disease-associated mutations in the J domain disrupt prion processing and protein 
refolding, they do so in a manner that is slightly different from that of G/F domain mutants.  
Given the limited knowledge of the clients of DNAJB6 in skeletal muscle and its role in 
disease, we hypothesize, as we did for the G/F domain mutations, that distinct variants may be 
associated with different levels of disease severity due to impairment of Hsp40 function to 
70 
 
varying degrees, or in different ways. Nonetheless, we are cautious to imply that a more drastic 
loss-of-propagation effect would correlate with or be causative of a more severe disease 
pathogenesis, as we have observed different degrees of aberrant chaperone function in the 
context of these disease-associated variants that are greatly dependent on client and conformation 
specificity. It is not uncommon for LGMDD1-associated mutations to have an effect in some but 
not all assays or when assaying specific client proteins (12, 37). Moreover, as we continue to 
understand and classify disease-associated variants as pathogenic, we should consider how 
variable clinical outcomes and disease severity may be influenced by factors such as variable 
expressivity and sex influences (11). Given these considerations, there is a need for simple 
models, such as the yeast system, by which we can understand if and how identified genetic 
variants affect chaperone function in order to better understand variable clinical outcomes within 
LGMDD1. Currently, we can only show that there are differences in adequate client processing 
and refolding although, undoubtedly, further in vitro studies are required to further elucidate the 
mechanistic cause of these functional defects and how they translate to pathogenesis. 
Lastly, we identified a novel phenomenon by which a mutated Hsp40, Sis1-S49V, 
appears to have a decreased steady state level of protein expression. This is, to our knowledge, 
the first known instance where steady-state expression of a chaperone is dependent on 
stabilization by a known substrate. Although serendipitous, this finding not only highlights an 
important function of chaperone-substrate interaction, but also hints at an additional role that 
specific substrates might play in chaperone function and protein homeostasis overall. Indeed, 
there is still much to be learned about co-chaperones, their function, interactions between 
themselves and with clients, and their role in disease pathogenesis. 
71 
 
2.5 Materials and methods 
2.5.1 Protein sequence alignment structure modeling.  
Protein sequences for DNAJB6b orthologs were found on UniProt and subsequently 
aligned to homologous disease-causing J domain mutations in Sis1. Sequences were visualized 
using BioEdit (77) with multiple sequences aligned through the use of ClustalW2 (77–79). 
Mutant DNAJB6b structures were generated through the use of using I-TASSER (80–82) and 
visualized using PyMOL (83). Structural comparisons and protein threading of variants to wild-
type protein structures was performed using wild-type Sis1 (PBD: 4RWU) (21). 
2.5.2 Yeast cultures and transformation.  
All experiments were performed in derivates of 74-D694 (ade1-14 his3-Δ200 leu2-3,112 
trp1-289 ura3-52). Yeast strains are [PSI+], [psi-], [RNQ+], or [rnq-], kindly gifted by S. 
Liebman (50, 84)  and J. Weissman (51). Yeast were cultured using YPD (1% yeast extract, 2% 
peptone, 2% dextrose), 1/4 YPD (0.25% yeast extract, 2% peptone, 2% dextrose) or synthetic 
defined (SD) media (0.67% yeast nitrogen base without amino acids, 2% dextrose) lacking 
specific amino acids using standard techniques. In order to study the function of sis1 mutants in 
the absence of wild type SIS1, previously described plasmid shuffle strains carrying pRS316-
SIS1 (37) were transformed with pRS314 (85) carrying sis1 mutants. We selected for colonies 
that lost wild type SIS1 through plasmid shuffle on plates containing 5-fluoroorotic acid (5-
FOA). Plasmid transformations were performed by the PEG/LiOAC method (86). Plasmid 
pRS316-Sis1 was a kind gift from E. Craig (17, 18). Plasmid 316-GPD-Lux was a kind gift from 
J. Weissman (67). Other plasmids are described below and were constructed using standard 
molecular techniques.  
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2.5.3 Plasmid Construction.  
Oligonucleotides used for site-directed mutagenesis are listed in Table 1. Using pRS314-
SIS1, the J domain LGMDD1 mutations were created by site-directed mutagenesis using the 
Agilent QuikChange II XL Sit’-Directed Mutagenesis Kit, as per manufacturer's instructions 
along with the following oligonucleotides: 1890 and 1891 (S49V), 1892 and 1893 (E53A), 1894 
and 1895 (N56L). Primer sequences were generated using Agilent's online primer design 
program. Mutagenesis was confirmed by sequencing the entire coding region of SIS1. 
2.5.4 Yeast Phenotypic Assays. 
For yeast spottings, cultures were grown overnight in selective media. Cultures were 
pelleted, washed, and suspended in water to an optical density of 0.1. The normalized yeast 
solutions were pipetted into a 96-well plate, and serial dilutions (1:5) were made using a 
multichannel pipette. Yeast were spotted onto plates using an ethanol-sterilized 48-pin replicator. 
To monitor cell growth or the [PSI+] status of yeast cells with the spread plate assay, overnight 
cultures were normalized by A600, serially diluted 5-fold, and spotted on the indicated media. 
[PSI+] status was assessed by colony color on large 145mm plates in rich 1⁄4 YPD media. Plates 
were incubated for 5 days at 30°C followed by overnight incubation at 4°C for additional color 
development. 
2.5.5 Protein Analysis.  
For boiled gel assays, yeast strains were cultured overnight. Cells were lysed with glass 
beads in buffer (25mM Tris-HCl pH7.5, 100mM NaCl, 1mM EDTA, protease inhibitors) and 
pre-cleared at 6,000 rpm for 1 minute at 4°C. Protein concentration of cell lysates was 
normalized using a Bradford assay and mixed with SDS-Page sample buffer (200mM Tris-HCl 
pH 6.8, 4% SDS, 0.4% bromophenol blue, 40% glycerol). Samples remained un-boiled and were 
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loaded on a 12% polyacrylamide gel and run under constant current of 110V until the dye front 
migrated halfway through the resolving gel. The current was then stopped, and the gel in glass 
plates was sealed in plastic and boiled upright for 15mins in a 95-100°C water bath. After 
boiling, gels were removed from the plastic cover and were reinserted in the SDS-PAGE 
apparatus, where voltage was re-applied until the dye migrated to the bottom of the gel. SDS-
PAGE was followed by standard western blotting with Sup35, Sis1, and Pgk1 antibodies. 
Sedimentation analysis for Rnq1 was performed as previously described (37, 48). Semi-
denaturing agarose gel electrophoresis (SDD-AGE) for [PSI+] was performed as previously 
described (37, 87). 
2.5.6 Luciferase Refolding. 
Luciferase refolding assays were performed as previously described (68). To monitor the 
ability of Sis1 to enhance refolding of luciferase in vivo, [PSI+] or [rnq-] yeast strains were 
transformed with the plasmid pRS316-GPD-Lux. Cultures were grown overnight in selective 
media and back diluted to an optical density of 0.3 in 8mL plastic culture tubes. Subsequently, 
cyclohexamide was added to a final concentration of 10ug/mL. Treated samples were then 
subjected to heat shock at 42°C for 22 minutes. Meanwhile, control samples were plated in 98-
well clear bottom plates and kept at 30°C. After heat shock, 200ul of each sample was plated in 
triplicate on 98-well clear bottom plates. All cultures were allowed to recover at 30°C. 
Luminometer readings were taken at 30, 60, 90 and, 120 minutes. For data analysis, each 
triplicate was averaged. 2way ANOVA was performed using GraphPad Prism version 8.1.1 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. 
74 
 
2.6  Acknowledgements 
We thank S. Liebman, J. Weissman and E. Craig for reagents. We also thank J. Daw for 
assistance with site-directed mutagenesis. We are appreciative of L. Dublin and A. Bhadra for 
helpful discussions and comments on the manuscript. 
75 
 
 
2.7 Figures 
 
 
 
 
Figure 2.1: Novel LGMDD1 disease-associated mutations were identified in the J-
domain of DNAJB6. (A) Amino acid sequence comparison of DNAJB6 and orthologs, 
including the yeast Hsp40, Sis1, aligned using ClustlW2. (B) Protein structure identifying 
homologous LGMDD1-associated mutations in the Sis1 J domain. 
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Figure 2.2: Homologous LGMDD1-associated mutations in the Hsp40 Sis1 differentially 
impair propagation of [PSI+] strains. (A) Yeast 74-D694 sis1∆ [PSI+] strains expressing wild-
type SIS1 or mutated SIS1 constructs were serially diluted 5-fold and spotted onto 1/4 YPD 
media and SD-Ade to monitor nonsense suppression of the ade1-14 allele (n=3). (B) [PSI+] 
colonies expressing the indicated constructs were isolated, grown in liquid YPD overnight, and 
plated on large 1/4 YPD spread-plates. An average of 626 colonies were counted and scored for 
strong [PSI+], weak [PSI+] or [psi-]/very weak phenotype. Data were collected from three 
separate biological replicates. (C) Representative western blot of yeast sis1∆ [PSI+] strains 
expressing wild-type SIS1 or mutated sis1 constructs. Cells were lysed and subjected to a boiled 
gel assay in order to display the amount of aggregated and monomeric Sup35 with antibodies 
against Sup35. Pgk1 is shown as a loading control. Standard protein markers are inappropriate 
for this particular assay and therefore are not shown (n=4-7). All samples were analyzed under 
the same experimental conditions. 
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Figure 2.3. Homologous LGMDD1-associated mutations in the J domain of Sis1 
differentially impair propagation of [RNQ+]. (A) Yeast sis1∆ cells harboring the indicated 
constructs and propagating low [RNQ+], very high [RNQ+] or [rnq-] were serially diluted 5-fold 
and spotted onto media in order to express the indicated SIS1 constructs and select for either loss 
of wild-type Sis1 (-Sis1) or co-expression of wild-type Sis1 (+Sis1). Cells were also spotted on 
rich media (YPD) (n=3). (B) Sedimentation assay to separate Rnq1 into soluble and insoluble 
fractions with expression of the indicated constructs (n=6). Total (T), soluble (S) and insoluble 
(I) fractions were subjected to SDS-PAGE and western blot probing for Rnq1. (C) SDD-AGE 
assay for the indicated constructs in low [RNQ+] and very high [RNQ+] strains (n=4-6). All 
samples were analyzed under the same experimental conditions. 
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Figure 2.4: A homologous LGMDD1-associated mutant in Sis1 exhibits impaired substrate 
refolding. (A) The capability for refolding luciferase was measured in Sc37 [PSI+] sis1∆ yeast 
strains harboring the indicated construct along with a plasmid expressing firefly luciferase (FFL). 
Yeast were normalized, treated with cycloheximide and subjected to heat shock at 42°C for 22 
minutes, followed by recovery at 30°C. Luminescence was measured at the indicated timepoints 
during recovery and normalized to luminescence of samples without heat shock treatment. The 
results represent the amount of luciferase refolding plotted as the percentage of recovery and 
represented as mean SEM (n=6). Each triplicate was averaged, (two-way ANOVA was 
performed; **p indicates a significant difference in Sis1-S49V FFL refolding relative to WT (p= 
0.002) at the indicated timepoint; ***p indicates a significant difference in Sis1-S49V FFL 
refolding relative to WT at the indicated timepoint (p<0.0001)). All samples were analyzed 
under the same experimental conditions. 
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Figure 2.5. The LGMDD1-associated J-domain mutation Sis1-S49V has reduced steady 
state levels in the absence of [PSI+]. (A) Representative western blot showing expression of the 
indicated constructs in [rnq-], low [RNQ+], and very high [RNQ+] strains. (B) Results represent 
the quantified protein levels of Fig 5A displayed as their ratio relative to WT. (C) Representative 
western blot of strong [PSI+] sis1∆ yeast expressing the indicated construct (left). The specified 
strong [PSI+] and Sc37 [PSI+] strains expressing the indicated constructs were passaged twice on 
3mM guanidine hydrochloride (GdnHCl) (cured), then grown on complete media without 
GdnHCl and lysed for SDS-PAGE followed by western blot (right). Pgk1 served as a loading 
control. (D) Results represent the quantified protein levels of Fig 5C displayed as their ratio 
relative to WT. For all Western Blot analyses, intensities were quantified and plotted as the mean 
SEM (n=3). Independent experiments indicating a significant difference in Sis1 expression levels 
relative to WT (paired t-test; n.s. nonsignificant; *p<0.05; **p<0.01; ***p<0.001). All samples 
were analyzed under the same experimental conditions. 
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2.8 Supporting Information 
 
 
 
Supporting Figure S1. Novel LGMDD1 J-domain mutations in Sis1 differentially impair 
propagation of [PSI+] strains and are rescued by expression of an additional WT-Sis1 copy. 
A, sis1∆ [PSI+] strains expressing a single copy of wild-type or mutated SIS1, and strains 
expressing an additional copy of wild-type SIS1 (+WT) were spotted onto YPD media (n=3). All 
spottings, minus the top (labeled [psi-]) are weak [PSI+] strains expressing the indicated 
constructs. 
81 
 
 
 
 
 
Supporting Figure S2. Sis1-S49V exhibits impaired substrate refolding while G/F-domain 
mutants do not. A, the capability for refolding luciferase was measured in [rnq-] sis1∆ yeast 
strains harboring the indicated construct along with a plasmid expressing luciferase. B, same as 
in A, but in Sc37 [PSI+] strains expressing wild-type or the mutated chimeric construct SDSS 
constructs instead of Sis1. Yeast were normalized, treated with cycloheximide and subjected to 
heat shock at 42°C for 22 minutes, followed by recovery at 30°C. Luminescence was measured 
at the indicated timepoints during recovery and normalized to luminescence of samples without 
heat shock treatment. The amount of luciferase refolding is plotted as percentage of recovery and 
represented as mean SEM (n=6). 
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S3 Fig. Sis1-S49V, does not show decreased steady-state levels when expressed in Sc37 
[PSI+] strain. (A) Representative western blot showing expression of Sis1 in Sc37 [PSI+] sis1∆ 
yeast strains harboring the indicated construct (n=3). Pgk1 is shown as a loading control. All 
samples were analyzed under the same experimental conditions. 
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S1 Table. Oligonucleotides used in this study. 
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Chapter 3: Elucidating the Mechanism of 
Molecular Chaperone Dysfunction Through 
the Use of Second-Site Suppressors  
 
 
 
 
 
 
The basis for this chapter arises from the unpublished findings of a second-site suppressor screen 
performed by a previous graduate student in the True lab, Kevin Stein. His work is highlighted in 
section 3.3.1 of this chapter. The work in subsequent sections was performed by Melanie Y. 
Pullen and is original to this dissertation. 
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3.1 Abstract 
Limb-girdle muscular dystrophy type 1D (LGMDD1) is an autosomal dominant 
myopathy characterized by late onset and proximal muscle weakness. LGMDD1 has been linked 
to mutations in the Hsp40 DNAJB6, a co-chaperone with anti-aggregation properties. 
Homologous proteins to DNAJB6 include Sis1, a J-domain protein in the yeast Saccharomyces 
cerevisiae (S. cerevisiae), and DNAJB1, the closest human homologue to Sis1; both proteins can 
maintain the yeast prion [RNQ+]. In this body of work, we performed a second-site suppressor 
screen using randomized mutagenesis and a cellular toxicity phenotype due to LGMDD1-
associated mutations in DNAJB1. From this screen we found six mutations that rescued the 
LGMDD1-associated viability defect. Moreover, we identified half of these mutants in the J-
domain, while the others were localized to the G-rich domain. We then used algorithmic 
structure predictions and protein threading to identify homologous mutations in our yeast DNAJ 
homologue. From these studies, we found no viability defects due to the addition of second-site 
suppressor mutations in yeast. This study provides insight into the intramolecular interaction of 
the J- and G/F-domains and how these might have an effect on canonical chaperone function. We 
hope to set the groundwork that will allow for identifying potential therapeutic approaches to 
LGMD. 
3.2 Introduction 
Chaperonopathies are diseases which arise due to aberrant molecular chaperone function 
(1). Molecular chaperones are crucial for protection against toxic protein misfolding and 
aggregation; as such, mutations affecting chaperone function often lead to disease (2–5). For 
example, the dominantly-inherited myopathy Limb-Girdle Muscular Dystrophy Type 1D 
(LGMDD1) is caused by mutations in the molecular chaperone, DNAJB6 (6). DNAJB6 belongs 
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to the J-domain protein (also called Hsp40) family of molecular co-chaperones (7). Although 
DNAJB6 has an important role in anti-aggregation (8–11), its client substrates are unclear. 
Mutations associated with LGMDD1 have been found in either the J- or G/F-domains of 
DNAJB6 (6). 
Suppression genetics is a powerful tool to identify new genetic sites of interest and 
provide insight into functionally interacting molecules and intersecting biological pathways (12). 
Here we used the yeast model system to perform a second-site suppressor screen using a viability 
defect of LGMDD1-associated mutations in the homologous DNAJB1 protein. Genetic 
suppression involves a suppressor mutation (a second mutation) which reverts a phenotypic 
effect caused by an existing mutation. The suppressor mutation thereby restores (or partially 
restores) a phenotype to the original state. There are two types of suppression, intragenic and 
intergenic. Intragenic suppressors result from a second mutation in the same gene as the original 
mutation. Intergenic suppression (also known as extragenic suppression) is a second mutation 
that alleviates the effect of a mutation, but that mutant is in another gene different from where 
the original mutation is located. Because DNAJB6 forms a functional homo-dimer (13), 
intragenic suppressors may be able to restore adequate chaperone function through either intra- 
or extra-molecular interactions. 
With the use of the genetically tractable yeast model system (14), we are able to perform 
such screens easily if the initial mutant shows a robust phenotype. Moreover, by identifying 
genetic changes that can revert the phenotype we can identify mechanistic alterations in 
DNAJB6 important for the rescue of LGMDD1 mutants (15). We discovered a screenable 
[RNQ+]-independent cell toxicity phenotype when we expressed the homologous LGMDD1-
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associated mutation DNAJB1-F90I (homologous to DNAJB6-F89I) in sis1∆ cells (16). Wild 
type DNAJB1 can complement for viability and [RNQ+] propagation in these sis1∆ strains (17, 
18). Multiple studies have assessed the functional consequences of the F89I mutation. These 
include, defects in polyglutamine (PolyQ) disaggregation, failure to complement Sis1, and 
defects in [RNQ+] and [PSI+] propagation in yeast, as well as defects in TDP-43 aggregation, 
and myotoxicity in zebrafish (16, 19, 20).  
The True lab previously created a chimeric protein replacing only the G/F domain of Sis1 
with that of DNAJB6 which allowed for disease-associated mutations to be expressed in the 
same G/F-domain found in humans presenting with LGMDD1 (16). The experiments herein take 
advantage of this chimera to study the effect of second-site suppressor mutations on protein 
structure and enhances our ability to perform assays in yeast.  
3.3 Results 
3.3.1 Identification of second-site suppressors 
 Mutations within the J- and G/F-domains of DNAJB6 are associated with LGMDD1 
(19, 21–26). Currently, our understanding of this disease’s pathology at the cellular level and the 
manner by which these mutations alter protein function is limited (6). Studies have attempted to 
elucidate how these disease-associated mutations alter DNAJB6’s anti-aggregation effects, 
nonetheless, only a few studies have successfully identified potential therapeutic approaches for 
disease treatment (6, 27, 28). We investigated whether the deleterious effects of LGMDD1-
causing mutations in an HSP40 chaperone could be rescued by second-site suppressors and in an 
effort to do so we turned to the yeast S. cerevisiae model.  In order to screen for second-site 
suppressors, Kevin Stein (a former graduate student in the True lab) identified a viability defect 
that could be used to screen for suppressors. Kevin Stein expressed a mutant DNAJB1 construct 
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expressing the homologous G/F domain mutation, F90I (homologous to DNAJB6-F89I). 
DNAJB1 is homologous to the disease-associated DNAJB6 but has a viability defect when the 
F90I mutation is expressed in the absence of a wild type SIS1 after plasmid shuffle (Figure 
3.1A). Using the DNAJB1-F90I construct, Kevin performed a screen using a library created by 
error-prone PCR mutagenesis for second-site suppressors that could revert this phenotype. These 
mutated plasmids were then transformed into yeast and expressed in the [RNQ+][psi-] 74-D694 
strain background. Kevin then performed a plasmid shuffle to select for expression of only the 
newly-mutated pRS314-DNAJB1 construct created by randomized mutagenesis and selected for 
colonies that lost wild type SIS1 through plasmid shuffle on plates containing 5-fluoroorotic acid 
(5-FOA). Because DNAJB1-F90I has a severe viability defect (Figure 3.1A), and only the 
mutated construct is expressed, this allowed for a high-throughput screen for viability. Viable 
colonies found from this screen are then further assessed to determine whether they are viable 
due to a rescuing second-site suppressor. 
In this screen, we identified six individual second-site suppressors which rescued the 
DNAJB1-F90I viability defect (Figure 3.1A). Interestingly, these suppressors rescue viability to 
varying degrees. Moreover, after sequencing we found that three second-site suppressors are 
located in the J-domain of DNAJB1, with the remaining suppressors located in the G-rich 
domain. One of the second-site suppressors, G68E, is located at the intersect of the J- and G/F-
rich domains (Figure 3.1B). Until now, these suppressors have not been studied in further detail. 
Within this body of work, we aim to identify whether second-site suppressors in the J-domain are 
able to completely (or partially) rescue Hsp40 function and the yeast prion propagation defects 
due to LGMDD1-associated mutations in the G/F-domain. 
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3.3.2 Structural analysis of homologous LGMDD1-associated mutations and 
second-site suppressors in the SDSS chimera  
The second-site suppressors identified in our screen appear to be localized near existing 
and potential (unconfirmed), LGMDD1-associated disease mutations. We were interested in 
studying how second-site mutations could modulate the tertiary structure of the protein in a way 
that could rescue the viability defect. First, we performed protein threading studies based on 
algorithmic prediction models of protein structure for the SDSS chimera. Although DNAJB1 
was used to find these suppressors, we were interested in being able to identify if and how these 
second-site suppressors can rescue the defects in prion propagation due to G/F-domain 
LGMDD1-associated mutations that we previously identified (16). Thus, we took advantage of 
the SDSS chimera that was previously constructed in the True lab (16). This chimera includes 
the G/F domain of DNAJB6 while maintaining the J-, G/M- and C-terminal domains of Sis1. 
Each domain is granted the first letter of the protein from which it originates, hence SDSS 
(Figure 3.2A). The use of this chimera allows us to assay specific known clients of the yeast J-
domain protein Sis1 while conserving the G/F-domain of DNAJB6 where the LGMDD1-
associated mutations are found.  
In Chapter 2 we demonstrated how protein threading and structure modeling allowed us 
to better understand the molecular interactions that are disrupted due to mutations (Figure 2.1). 
Therefore, we implemented a similar methodology in an attempt to better understand the rescue 
of the potential second-site suppressors we identified. Because we lack a published structure of 
our SDSS chimera, we created a 3D structure of the wild type SDSS and of the homologous 
SDSS-F89I (homologous to DNAJB1-F90I) mutation which we used in our viability screen. To 
do so, we submitted our sequence to I-TASSER (29). Interestingly, it appears the structure of 
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SDSS-F89I (homologous to DNAJB6-F89I) does not have any obvious alterations to the general 
secondary or tertiary structure of the protein when compared to wild type SDSS (Figure 3.3A). 
Furthermore, we assessed the potential interactions of SDSS-F89I (Figure 3.3B) with the second-
site suppressors identified in our screen. Upon doing so, we observe that the location of the 
second-site suppressors does not appear to be near the G/F domain mutations (Figure 3.3C). Due 
to time constraints, and an abundance of sequences currently being sent to the I-TASSER 
servers, we unable to submit the combinatorial primary sequences to generate additional models. 
Nonetheless, there is still a possibility that when these second site mutations are present there are 
changes to the secondary or even tertiary structure of this protein. Moreover, investigating any 
structural changes afforded by these mutations would also require studying of the protein as a 
functional homodimer. This will allow for a comprehensive understanding of the potential 
interactions of the disease mutations and second-site suppressors through intra- and extra-
molecular interactions. Currently, it is unclear what structural changes these second-site 
suppressor would cause. In addition, caution should be taken when considering these results as 
the C-score for the generated wild type SDSS and SDSS-F89I predicted structures are less than 
ideal (C-scores: -1.08 for SDSS-WT and -1.29 for SDSS-F89I). Unfortunately, little was gained 
from these structures and additional studies will need to address these shortcomings. Ideally, this 
analysis can be done with DNAJB1, DNAJB6 or a Sis1 structure. Unfortunately, those structures 
are incomplete and do not have the published G/F-domain structure to use in this modelling. 
3.3.3 Second-site suppressor mutations do not alter viability 
Our previous work has shown that a novel LGMDD1-associated mutation, Sis1-S49V 
(homologous to DNAJB6-A50V), which is located in the J-domain presents a growth defect in 
the absence of [PSI+] (in review, (30)).  Interestingly, we identified second-site suppressors 
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through our viability screen that are also located within the J-domain. Therefore, we wanted to 
study these second-site suppressors expressed in the SDSS chimera to elucidate whether they had 
detrimental effects on client processing or growth defects in our model system.  To do so, we 
only expressed the second-site suppressors (SDSS-2ss) without the LGMDD1 G/F-domain 
mutations. 
We hypothesized that a second-site suppressor which was capable of rescuing a viability 
defect in DNAJB1, such as those found in the screen, would be able to also rescue substrate 
processing defects of other G/F-domain LGMDD1 mutations. By this logic, we decided to use 
the SDSS chimera to create homologous second-site suppressors in the J-domain. This site-
directed mutagenesis was performed in wild type SDSS constructs as a series of controls and in 
combination with the previously described LGMDD1-associated G/F-domain mutations in 
SDSS. Table 3.1 demonstrates the plasmids created and transformed for the purpose of these 
experiments. 
In order to create these strains, we performed a plasmid shuffle as described in the 
methods section. After growing the cells overnight in selective liquid media, they were 
normalized by OD600 and plated in 5-fold dilutions to assess their growth. We plated cells on 
plates containing YPD media as a control for overall growth. We also plated these in three 
additional synthetic defined (SD) media: 1) plates lacking tryptophan (SD-Trp) which allowed us 
to select for expression of the SDSS-2ss plasmid, 2) plates containing 5-FOA and 3) plates 
containing SD-Trp plus 5-FOA. All plates containing 5-FOA select for colonies that lost wild 
type Sis1 and instead express the SDSS-2ss plasmid (Figure 3.4). Since the second-site 
suppressors identified in our initial screen are localized near existing and potential, disease 
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mutations we hypothesized that some suppressors may have deleterious effects when expressed 
by themselves, similar to that which we observed when Sis1-S49V was expressed. In fact, this 
would be interesting, since it may be an attractive way to screen for potential, unconfirmed 
disease-related mutations to verify whether they would be deleterious in the context of human 
disease. We found that expressing the second-site suppressors in the SDSS chimera does not 
appear to significantly alter viability when expressed in [RNQ+][psi-] strains (Figure 3.4). 
Although our previous findings demonstrated that expression of Sis1-S49V in these same 
[RNQ+][psi-] strains had a viability defect, it appears this is not recapitulated for these second 
site-suppressors located in the J-domain. 
3.4 Discussion 
The next step is to elucidate whether second-site suppressor mutations rescue the effect 
of specific LGMDD1-associated G/F-domain mutations on chaperone function and substrate 
processing. We hypothesize that second-site suppressors may rescue the observed LGMDD1-
mutant defects. Through the assessment of multiple LGMDD1 mutations, it is possible that some 
mutant and second-site suppressor combinations are more beneficial than others. This may occur 
due to probable changes in protein tertiary and quaternary structure caused by LGMDD1 
mutations and subsequent changes in structure due to the addition of second-site suppressor 
mutations. Also, the results from previously published work in the True lab suggest that not all 
LGMDD1 mutations affect [RNQ+] propagation and [PSI+] propagation in the same manner (16, 
30). Thus, it is possible that some second-site suppressors will have an increased beneficial effect 
on particular mutations.  
Given the results from our toxicity screen (Figure 3.1), we hypothesize that at least one of 
those second-site suppressors will rescue the F89I mutation. However, if none of the second-site 
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suppressors can rescue to some degree the effects of LGMDD1 mutations, a more extensive 
screen will need to be performed in order to identify other probable suppressors. 
3.5 Materials and Methods 
3.5.1 Protein sequence alignment structure modeling.  
Protein sequences for DNAJB6b orthologs were identified on UniProt and aligned to 
homologous disease-causing G/F-rich domain mutations in the SDSS chimera. Sequences were 
visualized using BioEdit (31) with multiple sequences aligned through the use of ClustalW2 (31–
33). Mutant SDSS chimera structures were generated using I-TASSER (29, 34, 35) and 
visualized using PyMOL (36). 
3.5.2 Yeast cultures and transformation. 
Experiments were performed using derivates of 74-D694 (ade1-14 his3-Δ200 leu2-3,112 
trp1-289 ura3-52). The yeast strains used are [PSI+], [psi-], [RNQ+], or [rnq-], kindly gifted by S. 
Liebman (37, 38)  and J. Weissman (39). Yeast were cultured using standard techniques in YPD 
(1% yeast extract, 2% peptone, 2% dextrose), 1/4 YPD (0.25% yeast extract, 2% peptone, 2% 
dextrose) or synthetic defined (SD) media (0.67% yeast nitrogen base without amino acids, 2% 
dextrose) lacking specific amino acids. In order to study the function of sdss mutants in the 
absence of wild type SIS1, plasmid shuffle strains carrying pRS316-SIS1 (16) were transformed 
with pRS314 (40) carrying sdss mutants. We selected for colonies that lost wild type SIS1 
through plasmid shuffle on plates containing 5-fluoroorotic acid (5-FOA). Plasmid 
transformations were performed using the standard PEG/LiOAC method (41). The pRS316-Sis1 
plasmid was a kind gift from E. Craig (18, 42). The SDSS chimera plasmid was previously used 
by the True lab and created by Kevin Stein (16). Other plasmids are described in the result 
section and were constructed using standard molecular techniques.  
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3.5.3 Plasmid Construction.  
Oligonucleotides used for site-directed mutagenesis are listed in Table 3.1. Using pRS314-
SDSS, the G/F-domain LGMDD1 mutations were created by Kevin Stein and previously 
published (16). Using the corresponding pRS314-SDSS-mutant plasmids, the homologous 
second-site suppressor mutations were created by site-directed mutagenesis using the Takara In-
Fusion HD Cloning Plus Mutagenesis Kit (43), as per manufacturer's instructions along with the 
following oligonucleotides: MP01 and MP02 (K24W), MP03 and MP04 (K28G), MP05 and 
MP06 (G68E) (Table 3.2). Primer sequences were generated using Takara’s online primer design 
program (44). Mutagenesis was confirmed by sequencing the entire coding region of SDSS. 
3.5.4 Yeast Spotting Assays. 
In order to perform yeast spottings, cultures were grown overnight in selective media. 
Overnight cultures were pelleted, washed, normalized and suspended in water to an optical 
density of 0.1. Then the yeast solutions were pipetted into a 96-well plate, and serial dilutions 
(1:5) were made using a multichannel pipette. Yeast were spotted onto YPD and synthetic media 
(SD) plates lacking specific amino acids using an ethanol-sterilized 48-pin replicator. Plates were 
incubated for 5 days at 30°C followed by overnight incubation at 4°C for additional color 
development before being photographed.  
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3.7 Figures 
 
 
 
 
Figure 3.1:  Intragenic suppressors from randomized mutagenesis screen alleviate 
DNAJB1-F90I toxicity. Screen performed by Kevin Stein. (A) Spottings are from the same 
plate and represent the indicated suppressors. (B) Illustration indicating the relative location of 
the second-site suppressors (black text) and the original mutation (red text) within the DNAJB1 
J- and G/F-domains. 
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Figure 3.2: Domain structures of DNAJB6, Sis1 and SDSS chimera. Top; Graphical 
representation of the domains for DNAJB6 (purple) and for Sis1 (orange). SDSS is represented 
as having all but the G/F-domain of Sis1, with its G/F-domain replaced with that of DNAJB6. 
Bottom; amino acid sequence of the J-domain and G/F-domains for DNAJB1, DNAJB6, Sis1 
and SDSS. Sequences were aligned using ClustaW2. Protein threading highlighted the 
homologous mutation sites and are highlighted using orange squares for the second-site 
suppressors and red squares to indicate the LGMDD1-associated mutations in the G/F domain. 
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Figure 3.3: Predicted protein structure of the SDSS chimera. (A) Aligned predicted 
protein structure of wild type SDSS (gray) and SDSS-F89I (green) the HPD motif  (magenta) 
and the J-domain (orange) are highlighted. (B) Predicted protein structure of wild type SDSS 
demonstrating the position of the three positions where homologous LGMDD1-associated G/F-
domain are found (red), the text besides the stick representation identifies the predicted position 
of the referenced amino acid. (C) Same as B, but also representing the predicted localization of 
the second-site suppressors (blue). Not shown is G68; due to its location it did not appear in this 
image. Images of these structures only represent amino acid positions 20-108 for simplicity. 
A
C
B
G/F Domain
J Domain
HPD motif
F89
P96
F93
G/F Domain
J Domain
HPD motif
F89
P96
F93
K24
K28
G/F Domain
J Domain
HPD motif
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Table 3.1: Plasmids created and used for this study. For ease of representation, the column on 
the left indicates the plasmid name, the middle columns indicate the G/F-domain mutation or 
second-site suppressor that is on the indicated plasmid. In addition, the plasmids that will be 
transformed and used as controls for these studies are indicated as such in the far-right column. 
The plasmids surrounded by the red square indicate those that were used for the experiments in 
Figure 3.4. Plasmids were created using site-directed mutagenesis as indicated in the Methods 
and Materials section. 
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Figure 3.4: Second-site suppressor mutations in the SDSS J-domain does not severely affect 
viability. Yeast sis1∆ cells harboring the indicated constructs and propagating medium [RNQ+], 
very high [RNQ+] or high [RNQ+] were serially diluted 5-fold and spotted onto media in order to 
express the indicated SIS1 constructs and select for either loss of wild-type Sis1 (5FOA and SD-
Trp,5FOA plates) or to allow for potential co-expression of wild-type Sis1 (SD-Trp). Cells were 
also spotted on rich media (YPD) as a control (n=3). 
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Oligonucleotide Description Sequence 
MP01 5’-SDSS-K24W 5’ACTGAAATGGGGTTATAGAAAAGCAGCTC 
MP02 3’-SDSS-K24W 5’TAACCCCATTTCAGTTCTTGCTCATTAG 
MP03 5’-SDSS-K28G 5’TTATAGAGGTGCAGCTCTAAAATATCATCCAGA 
MP04 3’-SDSS-K28G 5’GCTGCACCTCTATAACCCTTTTTCAGTTCTTGC 
MP05 5’-SDSS-G68E 5’TCAATACGAACTCGAGGCTGCTAGATCTGGTG 
MP06 3’-SDSS-G68E 5’TCGAGTTCGTATTGATCATATATTTCCC 
Table 3.2: Oligonucleotides used in this study. 
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4.1 Summary 
Chapter 1 highlights an overview of our knowledge regarding the fields of protein 
folding, prions in yeast and using yeast as a model system to better understand the molecular 
basis of chaperonopathies. Moreover, we review myopathies with a specific focus on LGMDD1. 
Chapter 2 focuses on the bulk of my thesis work and characterizes three novel LGMDD1-
associated mutations localized to the highly conserved Hsp40 J-domain. For these experiments 
we used the DNAJB6 homolog Sis1 in the budding yeast Saccharomyces cerevisiae. 
Homologous disease-associated mutants were assessed for propagation of [PSI+] and [RNQ+] in 
addition to refolding of heat-denatured firefly luciferase as a heterogenous chaperone client. 
Interestingly, these mutants were found to have varied effects on the different substrates, with 
Sis1-S49V in particular exhibiting prion and luciferase folding defects as well as instability that 
is rescued in [PSI+] but not [psi-] strains. Furthermore, Chapter 3 takes an innovative approach 
in an attempt to elucidate the mechanism by which these mutations lead to disease. The work 
highlighted in this section describes how second-site suppressors have the potential to rescue 
defects in molecular chaperone function. Subsequent studies may warrant translation into more 
complex disease models such as tissue cultures or animal models. 
This dissertation has laid the groundwork for future studies elucidating the effect of 
disease-associated mutations on molecular chaperone function and the potential of using second-
site suppressors as a means to better understand molecular chaperone dysfunction in the context 
of LGMDD1. We hope these findings will lead to future therapeutic developments. Chapter 4 
will describe future directions and the experiments that would continue to advance our 
knowledge in this area. 
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4.2 Future Directions 
Understanding chaperone function at the tissue and organ level is a large undertaking. 
Thankfully, the yeast system offers a tractable model which allows us to directly probe the 
cellular ramifications of mutated chaperones. The work herein has provided great insight into the 
consequences of three novel mutations associated with LGMDD1. Homologous mutations in the 
yeast Hsp40 Sis1 have allowed us to use the well characterized yeast prion proteins Sup35 and 
Rnq1 to assess the ability of yeast to propagate several strains of weak and strong prions. In this 
work, we have demonstrated alteration of normal prion propagation through biochemical, 
phenotypic and in vivo assays. We conclude that normal canonical chaperone function was 
altered by disease-associated mutations in Sis1. 
This work sets the stage in understanding the role that DNAJB6 may play in LGMDD1. 
Nonetheless, we do not yet have complete mechanistic insight into the manner by which these 
mutations affect the molecular chaperone network. Mutations in yeast chaperones are known to 
alter stable prion propagation, thus additional experiments would help elucidate the specific 
mechanism by which these mutations impact chaperone function and help identify therapeutic 
approaches for treating LGMDD1. 
4.2.1 Elucidating the mechanisms by which LGMDD1-associated mutations 
affect molecular chaperones and disease pathology. 
Assess the effect of LGMDD1 disease-associated mutations on Hsp40/Hsp70 ATP hydrolysis 
In Chapter 2 we found that three disease-associated mutations in the Sis1 J-domain 
affected client processing differentially, in a client and conformation specific manner. The most 
severe defect was due to expression of Sis1-S49V, although the other less severe mutants are 
only located a few amino acids apart (1). Currently, it is unclear whether the Sis1 mutants affect 
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client binding, Hsp70 binding, or Hsp70 ATPase activity. The interaction of J-domain proteins 
with Hsp70 is crucial for adequate functioning of the Hsp40/Hsp70 co-chaperone machinery. J-
domain proteins, such as Sis1, interact with Hsp70 through a conserved Histidine-Proline-
Aspartate (HPD) motif located in the J-domain that is required to stimulate ATP hydrolysis (2). 
Disruption of ATP hydrolysis due to mutations such as Sis1-H34Q, have demonstrated defects in 
substrate re-folding, again highlighting the importance of this interaction (2). We hypothesize, 
since Sis1-S49V had a stronger phenotype, that it is possible this mutant would have a more 
drastic modification of its normal ATPase stimulation capacity as compared to the other mutants. 
It is also possible that the prion propagation defect we have observed is mainly related to 
substrate recognition or substrate binding and/or release kinetics. This hypothesis is based on the 
possibility that the Sis1-S49V mutation affects the nearby salt-bridge between E50 and R73 (3, 
4). Since these mutations have the potential to affect the conformation of the protein, we can test 
whether they have an effect on the stability or structure of Sis1. Interrogation of the 
Hsp40/Hsp70 interaction could provide additional mechanistic insights. 
 In order to assess whether the deficiency caused by LGMDD1 mutations in Hsp40 is 
through modulation of Hsp70 ATP hydrolysis we would purify wild type and mutant Sis1 to 
perform ATPase assays with Ssa1 in addition to the Sis1 proteins. Initially, we would like to 
understand whether S49V has a greater impact on Hsp70 ATPase activity than wild type Sis1 or 
even in comparison with Sis1-E53A and Sis1-N56L. Since we have observed a defect in 
substrate refolding when Sis1-S49V was expressed in yeast and we know that ATP hydrolysis is 
an important step for substrate refolding, we hypothesize this defect may be due to decreased 
ATPase activity when this LGMDD1-associated mutation is present. 
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 Moreover, this comparison can also be performed with the purified wild type SDSS 
chimera and homologous G/F-domain mutated SDSS proteins. Since SDSS maintains the G/F-
domain of DNAJB6, we can use this chimera to assess the effect that homologous LGMDD1 
mutations in the J-domain or G/F-domain have on ATP hydrolysis. This will allow for a direct 
comparison into the mechanism by which G/F- and J-domain mutants may differ in their aberrant 
mechanism of action. Purified proteins would be incubated with a fixed concentration of ATP. 
At various timepoints, the amount of free Pi produced by hydrolysis of ATP to ADP would be 
measured. We would also purify and test the SDSS-mut/2ss chimeras (described in section 
4.2.2.1) to assess whether they can revert the effect of the mutations on ATP hydrolysis, if any.  
Lastly, Hsp40s have been shown to suppress aggregation of both prion and non-prion 
substrates (5–8). We would use the proteins we have purified to perform in vitro experiments to 
elucidate if refolding or suppression of aggregation are affected by the LGMDD1-associated 
mutations. We would be interested in assessing whether Sis1 mutants show differences in 
substrate refolding relative to each other or to wild type Sis1. For example, our in vivo FFL 
refolding assay showed a defect in client refolding when Sis1-S49V was expressed (Figure 2.4). 
Moreover, the interaction of Sis1 with the Hsp70 EEVD-motif is necessary for in vitro protein 
refolding and we know that mutations such as Sis1-E50A disrupt this interaction and FFL 
refolding (3). Therefore, if we hypothesize that Sis1-S49V alters Sis1 function in a similar 
manner as Sis1-E50A, we believe there may be defects in disaggregation and refolding of 
substrates. Therefore, we can perform in vitro assays looking at substrate refolding and we can 
assess suppression of protein aggregation using clients such as FFL, Sup35 or GFP (9). 
Furthermore, the question of substrate binding and release kinetics is still unanswered. To 
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address these questions in vitro binding assays, such as ELISA, may be performed to better 
understand whether there are defects in Sis1-substrate binding or even Hsp40-Hsp70 binding. 
 Elucidate the mechanism by which [PSI+] stabilizes Sis1-S49V steady-state expression 
Interestingly, the work highlighted in Chapter 2 identified conditional instability of Sis1-
S49V that is rescued in [PSI+] but not [psi-] strain backgrounds. This was a finding that, 
although serendipitous, is striking and unique; to our knowledge, this is the first instance where 
the presence of a specific client substrate has the capacity to stabilize the expression of a mutated 
chaperone. We believe this discovery is of interest and may help us understand how mutations in 
a J-domain protein may affect its interaction with specific client proteins. Therefore, we would 
like to understand the interaction between Sis1-S49V and Sup35 in its monomeric and 
aggregated forms.  
To do so, co-IP experiments should be performed to assess the interaction between Sis1-
S49V and Sup35 in [psi-] and also in weak and strong [PSI+] strains. By comparing the level of 
association between these proteins to wild type Sis1:Sup35 interaction we may gain insight into 
how the S49V mutation affects client processing. To test this, we would immunoprecipitate Sis1 
from [psi-] and [PSI+] cells and immunoblot for Sup35. Our hypothesis is that Sis1-S49V is 
unstable and being degraded in a [psi-] background, but that this mutation confers Sis1 with a 
higher affinity to [PSI+]. This hypothetical affinity to [PSI+] might protect Sis-S49V from 
degradation and therefore stabilizes steady-state expression. If Sis1-S49V does appear to have an 
increase in association with [PSI+] in comparison to wild type Sis1, then this would indicate that 
direct interaction between Sis1-S49V and [PSI+] could be responsible for maintaining steady-
state levels. Controls would include the bound fraction from the same sample not incubated with 
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antibody and results from [psi-] cells would serve as a control for monomeric Sup35 association 
with wild-type and mutated Sis1. In addition, we would perform IP experiments to assess the 
level of Sis1-S49V ubiquitination in the presence and absence of strong and weak [PSI+] strains. 
Assess for alteration in the cellular localization of mutated Sis1 
 DNAJB6b, as well as Sis1, have been shown to travel between the nucleus and the 
cytoplasm (10, 11). Since mutations in Sis1 alter the protein’s interaction with substrate, we 
hypothesize it is possible that expression of LGMDD1 mutations may affect Sis1 localization. J-
domain proteins such as Sis1 play an important role in client processing. Any deviations in 
normal chaperone localization are bound to have effects on adequate client processing which 
may lead not only to defects in prion propagation, but also to aberrant clearing of protein 
aggregates in the context of disease. To assess whether LGMDD1-associated mutations in Sis1 
affect chaperone localization we would use fluorescently tagged wild-type Sis1 and Sis1-S49V 
proteins (12, 13) and perform fluorescent imaging experiments to identify its localization within 
the cell. Controls for these experiments could include treatment of cells with the MG132 
proteasome inhibitor, which directs Sis1 localization to the nucleus. Complementarily, adding an 
N-terminal nuclear export or import signal has been shown to direct Sis1 to the cytoplasm or the 
nucleus, respectively (13). These experiments can be performed along with fluorescently tagged 
Rnq1 or Sup35 proteins to assess potential co-localization with Sis1.  
Assess whether discrepancies in [PSI+] phenotype of mutated Sis1 are due to cryptic [PSI+] 
oligomers 
 In our work, we observed that the distribution of Sup35 between monomer and aggregate 
fractions did not always correlate with phenotype in the weaker [PSI+] strains. For example, the 
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Sis1-N56L substitution blocks [PSI+] aggregate formation with no drastic phenotypic 
consequences (Figure 2.2). While Sis1-S49V clearly appears to be dysfunctional in these assays, 
Sis1-E53A and Sis1-N56L appear to be more variable depending on the assay being performed. 
Although strains expressing these mutations appear red in color (less nonsense suppression) on 
rich media and lack of growth on media lacking adenine (Figure 2.2A) when we introduced a 
wild type copy of SIS1 to these strains, we identified a partial rescue of the weak [PSI+] 
phenotype (Supporting Figure S1). This leads us to hypothesize that these Sis1 mutants, although 
phenotypically [psi-], result in propagation of cryptic [PSI+] propagons (14). I propose that this 
hypothesis be tested by fractionating total cell lysates through sucrose gradients which would 
indicate if there are indeed soluble, more SDS-sensitive Sup35 oligomers found in these strains. 
Moreover, this can be confirmed through yeast mating and sporulation experiments to test for the 
propagation of cryptic [PSI+].  
 Prion-based inheritance is unique in that it occurs entirely at the protein level rather than 
through modifications of gene expression. Prions are different from other amyloids in that they 
have the ability to seed the conversion of normally folded proteins into the prion state. 
Furthermore, prions segregate to daughter cells after division in a characteristic non-mendelian 
ratio (4:0 in S. cerevisiae). Therefore, in order to test for propagation of cryptic [PSI+] in our 
LGMDD1-mutated Sis1 strains, we would mate these strains to wild type [psi-] cells. The 
concept being that cryptic [PSI+] can transmit the prion state to a soluble pool of monomers (i.e. 
the [psi-] strains). These matings generate diploids and haploids from this progeny can be 
isolated and assayed phenotypically for [PSI+] propagation via tetrad analysis on YPD and SD-
Ade plates. These experiments will help us confirm and better understand the way by which 
mutations in the J-domain of Sis1 alter [PSI+] propagation. 
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4.2.2 Identifying therapeutic approaches for LGMDD1 using yeast as a model  
Do second-site suppressors rescue prion propagation defects due to LGMDD1? 
 The Hsp40/Hsp70 machinery is crucial for protein quality control. Specifically, Hsp40 
guides substrates to Hsp70 and promotes its ATPase activity. We hypothesize that LGMDD1 
mutants may affect Hsp40/Hsp70 interaction and/or function and that second-site suppressor 
mutations may rescue this phenotype. We aim to identify whether there is a complete rescue of J-
domain protein function and if the observed defects in yeast prion propagation are rescued by a 
second-site suppressor. This is a great example of how yeast genetics can guide us toward viable 
therapeutic options. Additional in vivo and in vitro biochemical analysis will provide insights for 
understanding how this complex chaperone-client interaction may be restored in LGMDD1 
mutants.  
 Previous work from the True lab showed LGMDD1 G/F-domain mutations in SDSS (15) 
and J-domain mutations in Sis1 differentially impair the processing of specific [RNQ+] prion 
conformers (Figure 2.3). The next logical step would be to assess the effect of the second-site 
suppressors on the propagation of [RNQ+]. These experiments were being set up and I hoped we 
could perform them in the very near future. Unfortunately, the pandemic caused by COVID-19 
has shut down operations and, even though the strains have been created, there was not enough 
time to complete these experiments. 
 Nonetheless, the experimental setup will be described for these experiments as they are of 
importance to this work and should be performed as soon as lab operations can be safely 
restored. As explained in Chapter 3, we introduced the SDSS chimera with an LGMDD1 
mutation and a second-site suppressor (SDSS-mut/2ss) in yeast cells harboring a particular strain 
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of [RNQ+]. Because Sis1 is required for cell viability, initially both wild-type Sis1 and the 
SDSS-mut/2ss plasmids were expressed and a plasmid shuffle was performed so that only the 
SDSS-mut/2ss plasmid is expressed. We hypothesize that second-site suppressors may revert the 
observed disruption in [RNQ+] propagation caused by LGMDD1-associated mutations. 
Therefore, the effect of SDSS-mut/2ss expression on [RNQ+] propagation should be studied in 
multiple [RNQ+] strains (medium, high, and very high). These strains were selected as they were 
shown to be most affected by the G/F-domain mutations (15). A series of experiments will be 
performed to better understand the impact of the second-site suppressors on G/F-domain mutant 
phenotypes such as the Rnq1 solubility assay and SDD-AGE.  
 Fluorescence microscopy is a commonly used method to evaluate the propagation of the 
[RNQ+] prion state and to differentiate the different single dot (s.d.) or multi dot (m.d.) [RNQ+] 
prion strains. Previous work has also shown that LGMDD1 mutations modulate the aggregation 
pattern of Rnq1 in vivo (15). Therefore, fluorescence microscopy should be performed to 
examine in vivo aggregate distribution of Rnq1. To perform these experiments, we will express a 
copper-inducible Rnq1-GFP fusion protein in addition to the SDSS-mut/2ss construct as 
previously published (15). This approach will allow us to identify changes in punctate versus 
diffuse fluorescence and observe any changes in localization patterns due to the second-site 
suppressors. 
 Experiments performed in the True lab have identified that LGMDD1 mutations in SDSS 
and Sis1 differentially impair propagation of [PSI+] strains (1, 15). Therefore, we should 
examine the effect of second-site suppressors on [PSI+] prion propagation, including the 
propagation of distinct [PSI+] variants. To do so, we will use sis1∆ cells propagating a particular 
122 
 
strain of [PSI+] such as one of the two weaker strains (Sc37 and weak [PSI+]) which had defects 
in prion propagation when the G/F domain mutations were expressed (15).  
We hypothesize that second-site suppressors may rescue the observed LGMDD1-mutant 
defects. Through the assessment of multiple LGMDD1 mutations, it is possible that some mutant 
and second-site suppressor combinations are more beneficial than others. This may occur due to 
probable changes in protein tertiary and quaternary structure caused by LGMDD1 mutations and 
the subsequent addition of second-site suppressor mutations. Also, our work suggests that not all 
LGMDD1 mutations affect [RNQ+] propagation and [PSI+] propagation in the same manner (1, 
15). Thus, it is possible that some second-site suppressors will have an increased beneficial effect 
on particular mutations. From the results of our toxicity screen (Figure 3.1), we hypothesize that 
at least one of those second-site suppressors will rescue the SDSS-F89I mutation. However, if 
none of the second-site suppressors can rescue the effects of LGMDD1 mutations to some 
degree, a more extensive screen should be performed to identify other probable suppressors. To 
perform these screens, we can use the [RNQ+] reporter protein (RRP) system to identify 
additional second-site suppressors with mutations generated through either EMS or error-prone 
PCR. Overall, these experiments will elucidate important structural changes that allow for the 
rescue of adequate chaperone function and whether second-site suppressors are a viable 
therapeutic approach for treatment of LGMDD1.  
Assess whether pharmacological modulation of Hsp70 activity is sufficient to rescue the 
deleterious effects of LGMDD1 disease mutations 
 Hsp40 interacts with Hsp70 by modulating client specificity and stimulating ATP 
hydrolysis (16). If the previous experiments (section 4.2.2) prove that there are, in fact, 
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alterations in ATP hydrolysis due to the disease-related mutations, it is possible that this defect 
might be rescued through pharmacological modulation of Hsp70 activity. Interestingly, one of 
the LGMDD1-associated mutants, S49V, is found in the J domain and near amino acids 
important for Hsp70’s ATPase activity (3). Furthermore, previous data has shown that disrupting 
the interaction of Hsp40 and Hsp70 is sufficient to rescue a toxicity phenotype caused by the 
F106L disease-related mutation in Sis1 (17, 18). This finding further highlights the importance 
of the Hsp40/Hsp70 interaction for proper protein homeostasis.  
 Pharmacological tuning of Hsp70 has been shown to modulate polyglutamine (polyQ) 
aggregation and toxicity in yeast (19). When Chafekar et al. performed this study, they used the 
dihydropyrimidine SW02 to stimulate Hsp70 ATPase activity and the related dihydropyridine 
CE12 to inhibit ATPase activity. As a result of this manipulation, they observed that increased 
Hsp70 activity caused a decrease in the amount of insoluble polyQ and increased toxicity. 
Conversely, decreasing ATPase activity increased polyQ aggregation and decreased polyQ 
toxicity. Data from the Weihl lab indicates that treating HeLa cells expressing disease-associated 
DNAJB6b mutants with SW02 (increasing Hsp70 ATPase activity) corrects LGMDD1 mutant 
disfunction (17). Thus, this is a great opportunity to use the yeast system to assess the effect that 
modulating Hsp70 activity may have on the aggregation of yeast prions in the context of 
LGMDD1 mutations.  
 To do so, cells expressing LGMDD1 mutant constructs in either the J- or G/F-domain, 
along with a wild type control, would be treated with either an Hsp70 activator or inhibitor and 
assayed to confirm that they indeed modulate Hsp70’s ATPase activity through an ATP 
hydrolysis assay. Afterwards, [RNQ+] solubility assays may be performed to test whether 
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modulating Hsp70 activity alters Rnq1 aggregation in SDSS-mut expressing cells. We have 
performed preliminary assays to confirm that pharmacologically treating SDSS-WT cells with 
SW02 or with VER-155008 (Hsp70 ATPase inhibitor) at various dosages has no adverse effect 
on cell growth (data not shown). These studies would present a better understanding of the 
therapeutic avenues that would be beneficial to patients with LGMDD1. 
Synergistic targeting of LGMDD1 phenotypes with second-site suppressors and concurrent 
modulation of Hsp70 ATPase activity 
Ideally, targeting LGMDD1 mutations through second-site suppressors or by modulating 
Hsp70 activity would rescue or substantially decrease the detrimental phenotypes we have 
observed from LGMDD1 mutations. Nonetheless, it is possible that these individual approaches 
would not be sufficient or that the mechanisms by which the mutations are defective are diverse. 
Thus, it would be interesting to test whether tackling those deficiencies through a combination of 
second-site suppressors and modification of Hsp70 ATPase activity is an efficient way to 
synergistically improve interaction between Hsp40/Hsp70 to rescue the deleterious effects of the 
disease mutant. 
 Cells expressing SDSS-mut/2ss constructs would be treated with an Hsp70 activator or 
inhibitor. After treatment, an array of assays may be performed to assess and compare the effect 
of synergistically treating LGMDD1 mutants with a second site suppressor or modulation of 
Hsp70 activity by itself. We would assess the propagation of [RNQ+] prion variants through 
[RNQ+] solubility assays, as well as [PSI+] prion propagation following our previously 
published methods. The results for this study will hopefully lead to the generation of potential 
therapeutic avenues for treatment of LGMDD1. 
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4.3 Conclusion 
 We hypothesize that there might be enough of a conformational or functional change in 
mutated J-domain proteins that ATP hydrolysis would be altered through the modified 
interaction of Hsp40 and Hsp70. It is also possible that LGMDD1 mutants do not affect Hsp40’s 
interaction with Hsp70 and that it is a matter of substrate recognition and/or release. If we 
consider that not all mutations are deleterious by means of the same mechanisms, we propose it 
may be possible to target LGMDD1 mutations in various manners: by using second-site 
suppressors, modulating Hsp70 ATPase activity modulation or by synergistically using second-
site suppressors and modulation of Hsp70 activity. Nonetheless, these experiments will be 
crucial to further our understanding of how these disease-related mutations are affecting protein 
homeostasis. 
In conclusion, this body of work will inform us on the mechanistic effects that LGMDD1 
DNAJB6 mutations might have on chaperone function. It will also further elucidate whether 
rescuing these deleterious effects is possible by second-site suppressors or modulating Hsp70 
activity. From this work, potential therapeutics may be designed to treat LGMDD1. 
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